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Chapter I - Introduction 
 
1. Pharmacogenomics and Personalized Medicine 
 
As long ago as 1959, the German pediatrician Friedrich Vogel suspected our genes being 
responsible for the individual effects of drugs and coined the term of pharmacogenetics 1. 
Previously, there was no logical explanation to the observation that some people benefit from a 
pharmacotherapy while others do not. Researchers advanced the field by extending our knowledge 
about pharmacological processes influencing individual drug effects: Between-patient differences 
in genes involved in pharmacodynamics (e.g. drug targets) or pharmacokinetics (e.g. drug 
metabolizing enzymes, drug transporters) might explain the observed individuality in drug efficacy 
and drug safety. With the deciphering of the human deoxyribonucleic acid (DNA) sequence and the 
development of genetic high-throughput methods, pharmacogenetics transformed more and more 
to pharmacogenomics where the interaction between single drugs and the whole genome is in the 
focus of attention. The results of the human genome project - which finished in 2001 - led to a rapid 
development of the new research area of pharmacogenomics 2. Since then, the most astonishing 
progress was done in the field of oncology where many new experimental results found their 
application in clinical routine (e.g. cobas® epidermal growth factor receptor (EGFR) mutation test 
kit 3). Recently, the therapy individualization of other indications like mental disorders became a 
greater focus of attention and it is widely assumed that personalized medicine - consisting of 
diagnosis and therapy based on individual environmental, phenotypic and genetic requirements - 
will be the future of psychiatric medical practice 4.  
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2. Depressive Disorders 
Depressive disorders are well-known since the times of the ancient Greeks - then named 
melancholia - and was attributed to an imbalance of the basic bodily fluids (blood, phlegm, yellow 
and black bile) 5. In modern times, according to the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-5), depression is defined by sad mood, loss of interest, appetite and concentration, 
sleep disturbances, fatigue, irritability, negative self-image and suicidal ideation 6. This group of 
diseases is characterized by a neurobiological pathology of the monoaminergic system, over-
reactivity of the hypothalamic-pituitary-adrenal (HPA) axis, dysfunction of amygdala and 
hippocampus and decreased levels of BDNF 7. Depressive disorders belong to the most prevalent 
mental illnesses in the world affecting over 350 million people with resulting deaths by suicide of 
approximately one million people per year 8. Furthermore, recent analyses predict that depressive 
disorders will account for the largest part of the economic burden within the next 20 years 9. The 
heritability for depression is reported at up to 40% and an early onset, presence of psychosis as well 
as a high degree of recurrence seem to be at least partially hereditable 10, 11. However, the mode of 
inheritance is complex with multiple gene sets being involved and it is further complicated by the 
impact of environmental factors 12, 13. The connection between candidate genes and depressions 
has been analyzed recently 14, but so far no genetic alterations that specifically lead to the 
development of depressions have been identified 15. 
 
2.1. Pathogenesis  
Even after decades of intensive research efforts the complex pathology of depressions still remains 
not completely understood. However, the previous investigations led to different theories that 
explain single aspects of the pathogenesis of depressions. The chemical hypothesis states there is 
an imbalance of mood-regulating neurotransmitters - especially serotonin, noradrenaline and 
dopamine - within the brain due to an increased clearance of these neurotransmitters from the 
synaptic cleft. The decreased activity of these neurotransmitters at the key sites in the brain is 
believed to be one of the leading causes of depressions. This was supported by the fact that the 
majority of antidepressant drugs are known to modify the neurotransmitter levels within the 
synaptic cleft (see chapter 2.3). Another hypothesis - the so called neurotrophic hypothesis - 
implies there are restructuring processes within the brain: Depressive patients show a volumetric 
decrease in mood-associated brain parts accompanied by a loss of activity 16. The most affected 
areas are the cortex (prefrontal and orbitofrontal), the amygdala and the hippocampus 17 amongst 
others such as the ventral striatum or the subgenual and anterior cingulate cortex 16. All these brain 
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parts obtain a role in depression-related functions like processing of emotions and feelings, reward 
system, mood control as well as anxiety, stress and fear reactions.  
Based on the fact that women are more affected than men 18, 19, the hormone-based hypothesis 
emerged as well. Changes in levels of corticotropin-releasing hormone (CRH), cortisol and estrogen 
were associated with a higher risk of depression 20 and symptomatic improvement due to 
antidepressants therapy is more effective after restoration of these hormones 21. At least partially, 
depressions seem to be caused by a chronic hyperactivity of the HPA axis leading to various neuro-
endocrine responses. Further investigations identified pro-inflammatory cytokines as potential 
mediators for depression (immunological hypothesis). Immune responses and neurodegeneration 
are tightly connected 22 and for instance higher concentrations of interleukin 6 and tumor necrosis 
factor (TNF) alpha were found in blood of depressed patients relative to healthy controls 23. 
Inflammation increasing factors such as obesity or smoking have been linked to depression as well 
24. Probably, cytokine effects in combination with a maladaptation to immune responses may lead 
to a chronification of symptoms of sickness behavior and therefore to depressions 25. Some of these 
hypotheses may partially overlap and still none of the mentioned hypotheses alone is able to fully 
cover the ontology of the complex disease of depression. 
 
2.2. Diagnosis and Prognosis 
In Germany, approximately twelve percent of the patients visiting a general practitioner suffer from 
depressive disorders and in approximately 25% of these cases no proper diagnosis is made 26. One 
reason for this is a variety of unspecific, co-occurring side symptoms (e.g. insomnia, weight 
changes, lack of concentration, libido disorder or pain). Furthermore, the differential diagnosis 
remains difficult and the method of choice to detect depressions is the usage of depression-specific 
questionnaires like Hamilton Depression Rating Scale (HDRS) or Beck Depression Inventory (BDI) 27, 
28. These questionnaires assign diagnosis based on symptoms of patient behavior (e.g. mood, 
feelings of guilt, suicide ideation, insomnia, etc.) interpreted by the physician or the patient itself. 
The disadvantages of the mentioned questionnaire based diagnostic systems are their inaccuracy 
and subjectivity. There are no objective, diagnostic biomarkers available to reliably predict the 
individual risk of the development of a depression. However, a serum based diagnostic laboratory 
test (MDDScore, Ridge Diagnostics) - based on activation of the HPA axis, metabolic, inflammatory 
and neurochemical pathways - was launched recently and is now commercially available but not yet 
well established and proven as a significant improvement in clinical practice 29. Although this is the 
first step to an objectification of diagnosis of depressive disorders, depression-specific 
questionnaires are still the methods of choice to detect depressions and to evaluate the progress of 
an antidepressant therapy.  
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Another promising and innovative approach is radiologic imaging of the brain because it has the 
potential to identify markers associated with underlying pathophysiologic processes in psychiatric 
disorders 30. According to recent research it could be able to support the differential diagnosis 
between Alzheimer's disease and depression in elderly people 31. Similar applications are 
conceivable to distinguish unipolar from bipolar depression or schizophrenia from depression and 
particular research efforts are done 32-34. Furthermore, individuals at high risk for depression and 
patients with chronic treatment-resistant depression have been reported with lower cortical 
thickness 35 and increased resting cerebral blood flow (CBF) in the medial prefrontal regions 36, 
respectively. Such parameters might become eventually useful as diagnostic or prognostic 
biomarkers in the future. In clinical practice depressive inpatients usually receive magnetic 
resonance imaging (MRI) measurements during the course of the disease 37. This is routinely 
performed to exclude cancerous, inflammatory, vascular or degenerative processes, but can be 
easily expanded to the mentioned applications. Such neuropsychological MRI measurements 
basically seem suitable as biomarkers for diagnosis of depression and however, will probably hardly 
replace the established rating scales, but might be useful as supplementary method to objectify and 
improve the diagnosis of depressions (see also chapter 4.2).  
 
2.3. Treatment  
The first two specific antidepressive drugs were the tricyclic antidepressant (TCA) imipramine and 
the monoamine oxidase (MAO) inhibitor iproniazid which were both discovered in the 1950s over 
the search of new antischizophrenic and antitubercolotic drugs, respectively 38. Pharmacodynamic 
studies revealed that TCAs reduce the presynaptic reuptake of neurotransmitters (e.g. serotonin, 
dopamine, acetylcholine, histamine, etc.) while MAO inhibitors (MAOI) reduce the degradation of 
monoamine neurotransmitters. During the following decades these groups were further developed 
which led to various similar antidepressants such as chlorpromazine or chlordiazepoxide and 
extended treatment opportunities. Only with the introduction of fluoxetine in 1987 the next crucial 
milestone of antidepressant drug development was achieved. Fluoxetine is the lead substance of 
the innovative drug family of selective neurotransmitter reuptake inhibitors that - in comparison to 
TCAs - excel by a superior side effect profile. Nowadays, these selectively acting drugs have largely 
replaced TCAs and MAOIs as the drug class of choice in the treatment of depressions due to a 
higher specificity, tolerability, safety and convenience 39. Selective serotonin reuptake inhibitors 
(SSRI) usually are considered the first-line drugs, although other selective neurotransmitter 
reuptake inhibitors such as serotonin-norepinephrine reuptake inhibitors (SNRIs) or noradrenergic 
and specific serotonergic antidepressants (NaSSAs) are available. An overview on the most 
important antidepressant drug classes including some representatives and their proposed 
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mechanism of action is given in Table 1. Typical side effects of antidepressants are weight changes, 
insomnia, increased suicidal risk, libido loss and erectile dysfunction. 
 
Table 1: Overview on antidepressant drug classes. 
class lead drugs proposed mechanism of action 
TCA 
Amitryptiline 
Imipramine 
Nortriptyline 
inhibition of transporters for serotonin and norepinephrine 
modulation of serotonergic, adrenergic, glutamatergic, cholinergic and 
histaminic receptors  
MAOI Selegiline inhibition of monoamine oxidase 
SSRI 
Citalopram 
Fluoxetine 
inhibition of serotonin reuptake transporters 
SNRI Venlafaxine inhibition serotonin and norepinephrine reuptake transporters 
NaSSA Mirtazapine modulation of adrenergic and serotonergic receptors 
NRIs Reboxetine inhibition of norepinephrine reuptake transporters 
TCA - tricyclic antidepressants, TeCAs - tetracyclic antidepressants, MAOI - monoamine oxidase inhibitors, SSRI - selective 
serotonin reuptake inhibitors, SNRI - Serotonin-norepinephrine reuptake inhibitors, NaSSA - noradrenergic and specific 
serotonergic antidepressant, NRIs - norepinephrine reuptake inhibitors 
 
 
Although there are several mechanisms of action, all antidepressive drugs are believed to modify 
neurotransmitter levels by one means or another. However, this does not explain the delay in 
clinical improvement which is observed three weeks at the earliest after beginning of an 
antidepressant therapy because the pharmacological modulation of neurotransmitter systems 
occurs rapidly within a few hours. Thus, this mechanism might be only an initial event of 
antidepressant effects followed by a series of intraneuronal events such as changes in neural gene 
expression, functional adaptation, neurotrophic processes and synaptogenesis. Effective 
antidepressant treatments seem to normalize the structural and functional abnormalities found in 
the brains of depressive patients 40, 41. For instance, chronic treatment with antidepressants leads to 
an increased proliferation in the hippocampus 42 and mood stabilizers such as valproate or lithium 
are thought to increase proliferation and survival of hippocampal neurons 43, 44. Interestingly, 
electroconvulsive therapy1 45, 46 also increases hippocampal neurogenesis 47. Thus, neural 
proliferation and neuroplasticity modulated by antidepressive therapy probably leading to a 
reversal of hippocampal atrophy 48, 49. Further, the treatment of patients with smaller hippocampi is 
                                                          
1
 Electroconvulsive therapy is an alternative approach for the last-line treatment of depressions where 
seizures are electrically applied to the brain. The efficacy is comparable to antidepressants but it requires 
comedication with anesthetics and muscle relaxants as well as expensive device, and may have adverse 
effects like confusion and memory loss. 
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prolonged over weeks 50. One of the key players in this proliferative action seems to be the brain-
derived neurotrophic factor (BDNF) whose gene expression is significantly upregulated in the 
hippocampi of animals treated with antidepressant drugs such as citalopram or imipramine 51, 52.  
 
2.3.1. Antidepressant Response Biomarkers 
The latest S3 guideline for unipolar depression lists ten drug classes with 27 antidepressants 
(including more than 3,000 licensed medications in varying dosage, administration ways, 
technological modifications, different producers etc.) that are recommended for the treatment of 
moderate and severe forms of depressions 53. Despite (or because of) the given variety of 
antidepressive drugs the individual therapy success is still in need of improvement due to low 
response rates. Up to 50% of patients show no adequate improvement in their clinical state after 
treatment with first-line antidepressant medication 54. An early symptomatic evaluation of 
individual therapy success is complicated by a delay in clinical improvement of several weeks up to 
months and the applicability of biomarkers in psychiatry is still in its infancy 55, 56. Approximately a 
third of the initial non-responders to antidepressant drugs will achieve remission over the following 
course of the treatment regimen (without switch of medication) 57. During this period of non-
response the compliance might decrease and the clinical conditions could decline which also may 
cause an increase in suicidal risk. To improve the treatment efficacy pre-therapeutic knowledge 
about the expected clinical success would be highly beneficial. However, so far it is impossible to 
predict the individual treatment outcome of depressive patients due to a lack of predictive 
biomarkers and convincing pharmacogenomical studies (e.g. reviewed by Narasimhan & Lohoff 58). 
The main reason for this lack might be the high heterogeneity of psychiatric diseases and the 
complexity of the CNS aggravating the study of the underlying mechanism of individual therapy 
effects as well as a lack of basic knowledge due to the absence of adequate animal models. On this 
account, both choice and dosage of antidepressant drugs is still dependent on trial and error 
prescription and are routinely administered by clinical knowledge of the particular physician 59.  
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3. Drug- and Disease-induced Depressions 
Depressions frequently occur as concomitant diseases in a variety of psychological and non-
psychological disorders. A higher prevalence of depression was observed in patients suffering from 
chronic inflammation like cardiovascular diseases, type 2 diabetes or rheumatoid arthritis 60, 61 and 
for instance, the prevalence of depression in patients with coronary heart disease is three times 
higher compared to the general population 62. In addition, levels of inflammatory blood markers 
such as cytokines, chemokines or acute phase proteins are increased in patients with severe 
depression inferring a relationship between inflammation (i.e. immune system activation) and 
depression 23, 63-65. According to Dantzer et al. inflammation might increase the risk to developing 
depression more than the traditional psychosocial factors (e.g. negative life events, chronic stress 
or lack of social contacts) 25.  
Depressions belong to the most important psychiatric comorbid conditions in neurological 
disorders like multiple sclerosis (MS) 66 which accompanies with a decrease in quality of life and an 
increase in disability 67. In comparison to other chronical, non-neurological diseases, depressions 
have a higher incidence in MS 68-70 and the highest rate beneath other neurological diseases like 
epilepsy or amyotrophic lateral sclerosis 71. Depressions occur in approximately 30% of patients 
with MS in an early phase of disease progression 72, 73 and the more severe the MS the higher the 
likelihood of depressiveness 74. Therefore it is recommended to screen MS patients for depression 
during follow-up visits 75, 76. MS and depressive disorders share elevated serum concentrations of 
cytokines and decreased hippocampal volumes 77, 78. Additionally, depressed MS patients show 
greater atrophy of anterior temporal regions and more hyperintense lesions in medial frontal 
regions 79. The diagnosis of depression in MS is challenging due to overlapping symptoms (e.g. 
fatigue, insomnia, altered appetite, cognitive dysfunction, memory and concentration impairment) 
80 and therefore, depression frequently remains undiagnosed and untreated 81. Based on the rate of 
depression in MS, numerous suicides are recorded in MS patients 82, 83, with a 7.5 higher risk 
compared to the healthy population 84. MS is the most common autoimmune disorder affecting the 
central nervous system (CNS) and the most common progressive disorder of young adulthood 85. It 
is characterized by chronic inflammations of the brain resulting in axon demyelination and 
breakdown of the blood-brain-barrier (BBB) causing the typical symptoms (e.g. ataxia, tremor, 
nystagmus etc.). Neurochemical, structural and immunological aberrations seem to have a 
fundamental impact on the pathogenesis of depression in MS, although the underlying mechanisms 
remain controversial and seem to be a multifactorial response to this chronic progressive disease 86. 
One hypothesis implies humoral responses to inflammation or stress being responsible for the 
development of sickness behavior which in turn might become chronic and therefore abets the 
pathogenesis of depression 25. Psychosocial reasons based on stress reactions to diagnosis, 
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uncertain prognosis, impending disability and missing social support are known to further worsen 
the depressive symptoms in MS 87. The most commonly used disease-modifying drugs are 
interferon beta, glatiramer acetate, mitoxantrone, natalizumab, fingolimod and dimethyl fumarate 
with a high variability in treatment response 88. Interferons are able to decelerate the progression 
of disability and to reduce the rate of MS relapses 89, 90 through immunomodulatory their properties 
91. Unfortunately, interferons are also reported to be able to induce depression and depression-like 
behavior: Treatment with interferon alpha leads to depression in approximately a third of patients 
92-95 while interferon beta is also thought to be causative for depressive side effects with varying 
occurence rates 96-99. These symptoms might be based on effects on serotonergic pathways because 
they can be prevented by pretreatment with SSRIs 100 and patients with genetic serotonin 
transporter (SERT) variants are more likely to develop a depression during interferon administration 
101, 102. However, drug-induced depression is not limited to a particular group of drugs, but has been 
associated with cardiovascular agents, anti-infectives, CNS drugs, dermatologic agents, hormonal 
treatments and chemotherapeutic drugs 103, 104. Some possible molecular mechanisms are 
postulated in the literature suggesting an impaired functionality of neurotransmitter systems - 
especially norepinephrine, dopamine, serotonin and gamma-aminobutyric acid - as a consequence 
of drug intake 105. For instance, a decrease of blood tryptophan (a serotonin precursor) levels was 
reported due to an immunotherapy-induced activation of the tryptophan metabolizing enzymes 
tryptophan 2,3-dioxygenase and indoleamine-pyrrole 2,3-dioxygenase 106, 107. Hence, depressions 
might also be induced by drugs targeting the immune system whereby patients with physiological 
(e.g. over-reactive HPA) 108 or psychological (e.g. higher depressiveness scores before initial therapy 
with drug-inducing agents) risk factors are more likely to develop severe depressions 109. 
Furthermore, isotretinoin - a drug used for the treatment of cystic and therapy resistant acne - is 
suspected to induce depressions 110, 111 as well as the anticonvulsant primidone 112 and in general, 
corticosteroids 113 and oral contraceptives 114. Summarizing, drug-induced depression is a frequently 
observed phenomenon - including a variety of different drug classes and indications - which has an 
extensive impact on therapy compliance, individual well-being and the economics of the health 
care system. A better understanding of the mechanism behind drug-induced depressions is 
required.  
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4. Personalized Medicine of Depressive Disorders - Novel Approaches 
 
4.1. Cell Based Approaches 
Recent research focuses on integrating latest neurobiological findings of depressions to help 
guiding individual treatment more efficiently and the search for genetic biomarkers predicting 
individual clinical response has become the main focus of biomedical research in the area of 
psychiatric diseases. Numerous studies have investigated genetic characteristics such as mutations 
or SNPs (single nucleotide polymorphisms) for associations with antidepressant drug response, but 
the majority of the outcomes missed replication or even showed opposite results in subsequent 
studies 58, 115. For that reason, other approaches away from simple DNA characteristics towards RNA 
or protein properties are needed to study the individual clinical response to antidepressants, i.e. 
focusing on the more complex inter-individual variability in gene expression 116. One promising 
approach is the usage of lymphoblastoid cell lines (LCLs) to study individual antidepressant drug 
effects on gene expression under well-controlled, laboratory conditions. This was recently 
employed by several working groups 117-119 and further, will be within the devoted attention of the 
present work. LCLs are B-lymphocytes immortalized by Epstein-Barr-virus (EBV) transformation and 
due to their broad availability and potency to reflect individual patient’s features they are 
promising models in biomarker research in psychiatry. More than 4,100 brain transcripts are 
expressed in blood cells and gene expression between B-lymphocytes and LCLs is strongly 
correlated within same individuals 120. This and the fact that LCLs express more than 50% of all 
human genes in general make them suitable models to study antidepressant-induced changes in 
gene expression.  
 
4.2. Neuroimaging Approaches 
As already stated in chapter 2.2, radiologic imaging of the brain has the potential to identify 
markers associated with underlying pathophysiologic processes in psychiatric disorders and MRI 
measurements probably will be useful tools to detect diagnostic or prognostic biomarkers in the 
future. MRI is a non-invasive imaging technique used for a wide range of medical applications like 
diagnosis of diseases or injuries (e.g. neurological cancers, joint diseases) as well as for medical 
research. In contrast to X-ray computed tomography, the main advantage of MRI is the absence of 
ionizing, mutagenic radiation. In the past, the primary aim of MRI in psychiatry was to measure 
neural correlates of mental disorders in order to identify changes in locations and magnitudes of 
neuronal structure and function under pathological conditions. Nowadays, neuroimaging focusses 
on the application of these parameters as biomarkers to support diagnosis, assess potential risk 
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factors and to predict the efficacy of psychotropic drugs 121. By improving our understanding of 
individual pathogenic mechanisms of neuronal diseases, MRI allows the development of new drug 
therapies and potentially provides high sensitive measurements of treatment response in 
genetically defined cohorts 122.  
We differ between two main types of MRI: structural imaging (sMRI) and functional imaging (fMRI). 
Structural and functional alterations in the brain are strongly connected in psychiatric disorders and 
hence, fMRI is a promising neuroimaging tool to analyze neural activity associated with 
psychotropic drug effects like attention, emotional processing or reward-related reactions 123, 124. 
Thus, fMRI provides additional neuroimaging phenotypes for pharmacogenomical research. The 
advantages of fMRI perfusion imaging are its quantifiable results and the high level of repeatability 
rendering it a powerful tool to visualize drug effects in clinical studies 125. Changes in CBF and 
therefore in neural activity during psychological tasks and processes can be visualized. 
Consequently, specific brain structures can be addressed depending on the chosen paradigm 126. To 
date, there are only a few neuroimaging studies available investigating the impact of the 
relationship between cerebral properties and genetics on psychiatric treatment. However, the 
impact of MRI to our knowledge acquisition regarding psychiatric diseases has been huge in the 
past decades and so it is not surprising that many of the described abnormalities of the depressed 
brain (see chapter 2.1) are based on findings from MRI studies. Further, manifold results support 
the applicability of MRI measurements in the context of personalized medicine of depressive 
disorders, especially in the field of diagnosis and monitoring depressions 127. The main challenge is 
to transfer the findings from clinical research into clinical practice. Therefore, it is required to better 
understand the individual variability of functional brain level connectivity underlying depressive 
disorders by MRI methods in order to improve the personalized medicine approach of depressive 
disorders.  
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Chapter II - Aims of the Project 
 
Since the mechanisms and molecular backgrounds of the high individual variability of depressive 
disorders and the particular treatment efficacy has not been sufficiently understood so far, we 
focus on the identification of potential biomarkers by application of different approaches - cell 
based (I) and neuroimaging based (II) - to further advance the field of personalized medicine of 
depressive disorders. 
 
(I) The current therapy success of depressive disorders remains in need of improvement due to low 
response rates and a delay in symptomatic improvement. Whereas depressions are associated with 
decreased hippocampal neurogenesis, antidepressant treatments seem to have the opposite 
action. They stimulate cell proliferation as well as the survival and maturation of neurons and 
therefore, modulate neuroplasticity. A link between hippocampal neurogenesis and the therapeutic 
action of antidepressants was suggested based on animal studies 128. It is hypothesized that 
irreconcilable hippocampal neurogenesis deficits cause non-response to antidepressant therapy 129. 
Thus, a connection between hippocampal neurogenesis (i.e. neuronal proliferation) and individual 
clinical effectiveness of antidepressants in patients suffering from depressive disorders is proposed 
130. Here, we want to study the effects of antidepressants on cellular proliferation rates by usage of 
human LCLs derived from depressed patients as model systems. The main focus of this project is to 
investigate the relationship between individual clinical response and the peripheral, 
antidepressant-modulated proliferation in patient-derived LCLs. Further, we are aiming at the 
identification of tentative neuroplasticity-associated gene expression biomarkers for the treatment 
individualization of depressive disorders. To this end a hypothesis-free approach using genome-
wide gene expression profiling helps us to further improve our understanding on the individuality 
of antidepressant effects on both a molecular and a genetic level as well as of the underlying 
mechanisms of action of antidepressants. 
(II) In a clinical study we focus on the affective side effects of the cytokine interferon beta which is a 
potent drug for the treatment of MS. Interferons are widely suspected to trigger depression-like 
behavior after long-term administration: Approximately one third of patients treated with 
interferon alpha develops symptoms of depressions 92. Similar effects of interferon beta were 
reported 131, but are not well researched until now. The neurobiological correlates and pathogenic 
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mechanisms of these affective symptoms remain unknown. One open issue concerns the 
mechanisms at system level through which interferon may produce psychological symptoms 
because it is unclear whether these symptoms arise from interferon beta treatment itself or as a 
side symptom from the progressing disease of MS. In the absence of clinical studies in healthy 
cohorts, the roles of interferon medication and those of the underlying diseases cannot be 
distinguished 132. Here, we want to identify evidence for the depression-inducing effect of the 
cytokine interferon beta by psychometric testing and by measuring changes of brain activation 
patterns in depression-related brain areas. To this end, we will investigate interferon beta mediated 
change in brief functional neuroimaging probes of emotional function such as amygdala reactivity 
on viewing emotionally arousing stimuli 133 or neural correlates of reward anticipation 134. These 
two aspects of information processing were chosen as representative of well-known, important 
features of depressive functioning: lack of sensitivity to reward (anhedonic symptoms) 135 and 
hyperreactivity to negative emotional stimuli 136. The functional imaging aims at assessing change in 
intermediate phenotypes related to interferon beta mediated psychotropic side effects and so this 
study will help to clarify if typical neural correlates of depressive mood are detectable in individuals 
receiving interferon beta treatment.  
 
 
  
Chapter III - Material and Methods 
13 
 
 
Chapter III - Material and Methods  
 
1. Cell-based Methods 
A register of the used lab equipment, disposables, chemicals, solutions, media and kits including 
the names of the manufacturers and their particular office is listed in the Supplement (pp. 139).  
 
1.1. Human Lymphoblastoid Cell Lines 
 
1.1.1. Origin and Patient’s Characteristics  
LCLs were derived from two different antidepressant studies: the Munich Antidepressant Response 
Signature (MARS) project and the Sequenced Treatment Alternatives to Relieve Depression 
(STAR*D) study. The studies were approved by respective Ethical Committees. Participating 
patients gave verbal and written informed consent to provide biomaterial for the study of 
antidepressant response biomarkers also including transformation of blood lymphocytes into cell 
lines. An overview on the study population used in the presented work is given in Table 2. Complete 
patient’s characteristics and drug profiles are listed in the Supplement (pp. 142). 
 
Table 2: Characteristics of the MARS and STAR*D LCL study cohort. 
  MARS STAR*D 
  total NR R total NR R 
gender 
male 
female 
24 
26 
10 
15 
14 
11 
24 
26 
14 
11 
10 
15 
age years 49.9 ± 11.8 51.6 ± 11.4 48.3 ± 12.2 48.5 ± 11.8 48.8 ± 9.5 48.3 ± 13.9 
depression 
scale* 
initial 
final 
27.0 ± 7.4 
11.8 ± 8.7 
25.5 ± 8.2  
18.7 ± 5.1 
28.6 ± 6.3 
4.8 ± 5.0 
17.9 ± 3.2 
9.0 ± 7.2 
18.9 ± 3.1 
15.5 ± 3.9 
16.9 ± 3.0 
2.6 ± 1.9 
different 
antidepressants 
number 4.0 ± 1.6 2.3 ± 0.9 1.6 ± 0.6 1.0 ± 0.0 1.0 ± 0.0 1.0 ± 0.0 
* MARS: Hamilton Depression Rating Scale; STAR*D: Quick Inventory of Depressive Symptomatology 
NR - non-responder, R - responder 
 
The MARS study was a naturalistic clinical study on antidepressant drug response designed for 
pharmacogenetics analyses of antidepressant drug response biomarkers 137-139. EBV transformed 
LCLs were generated in a subset of patients from the MARS project. LCLs were gained by EBV 
transformation from full EDTA-blood samples provided by the MARS patients that have been 
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admitted for depression treatment to the hospital of the Max Planck Institute of Psychiatry in 
Munich, Germany 137. MARS was an observational study of depressed patients being treated 
according to the attending physician’s choice. Depressive symptoms were rated by the 21-item 
HDRS at weeks 0, 5 and 8 after study inclusion 27. Response was defined as HDRS reduction of at 
least 50% (compared to initial values at study inclusion) and remission was achieved after a total 
reduction of HDRS to values smaller than eight 140. STAR*D was an open label, randomized, 
multicenter, controlled clinical study aiming on the definition of effective subsequent treatment 
strategies after a first unsuccessful antidepressant therapy 141. All patients were diagnosed with 
unipolar depression and were treated with a citalopram monotherapy at the initial phase of this 
study. A total of n=50 cell lines were obtained, derived from patients with Caucasian origin that 
have been treated with citalopram in defined doses. Depressive symptoms were rated by Quick 
Inventory of Depressive Symptomatology (QIDS) 142 over the course of up to 14 weeks. LCLs were 
purchased from the NIMH Center for Collaborative Genetic Studies. They were chosen to cover 
n=25 first-line therapy responders to citalopram (with more than 50% decline of depressive 
symptoms during the first month) and n=25 treatment resistant patients (with no response or 
remission during the whole treatment algorithm of the STAR*D study).  
 
1.1.2. Generation  
LCLs were generated from lymphocytes isolated from blood samples through EBV transformation 
143, 144. Peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation 
using Ficoll. The cell pellet was resuspended in 800 µl EBV-supernatant from B95-8 cell line and 100 
µl each were seeded into eight wells of a 48-well cell culture plate. After addition of 200 µl RPMI 
(Roswell Park Memorial Institute) medium containing 20% fetal calf serum (FCS) per well, cells were 
incubated at 37°C in a humidified CO2 incubator (with 5% CO2). After five days, one volume of fresh 
RPMI medium (containing 20% FCS) and cyclosporine A (in ethanol) were added to a final 
concentration of 1 µg/ml. On day 23 to 26 after isolation, cells were further cultivated in T25 cell 
culture flasks with exchange of the medium (containing 15% FCS) every second day. To control the 
process of LCL generation (i.e. the accumulation of B lymphocytes and the non-accumulation of T 
lymphocytes), cell identity was tested regularly using the T- and B-cell specific antibodies CD3, CD19 
and CD45 (TritestTM Kit): 100 µl of cell suspension was incubated with 10 µl of TritestTM solution for 
30min at 4°C. After erythrocytes cell lysis using 5ml of FACS (fluorescence-activated cell sorting) 
lysis buffer and centrifugation (4000rpm, 2min, Pico centrifuge), the cell pellet was washed with 
1ml of NaCl solution (0.9% w/v), resuspended in 250 µl of NaCl solution (0.9% w/v) and transferred 
to a FACS tube. Subsequently, flow-cytometry measurements were carried out (Figure 1). 
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Figure 1: Cell identity before (day 0) and after (day 50) EBV transfection measured by cell specific antibody based flow 
cytometry. Over the time the cellular distribution shifts to B lymphocytes whereby T lymphocytes disappear from the 
culture constitution.  
 
1.1.3. Mycoplasma Testing 
Since mycoplasma infections are not detectable microscopically, enzyme-linked immunosorbent 
assays, i.e. MycoAlertTM Plus Mycoplasma Detection Kit, were used according to the manufacturer’s 
instruction. The presence of mycoplasmal enzymes is exploited by a selective biochemical test 
based on the conversion of ADP (adenosine diphosphate) to ATP (adenosine triphosphate). A cell 
suspension aliquot is transferred to a sterile microcentrifuge reaction tube and pelleted at 200 x g 
for 5 min. To 100 µl of the supernatant in a sterile 96-well plate, 100 µl of MycoAlertTM Plus Reagent 
is given to each sample. After an incubation time of 5 min, the luminescence was measured in a 
Safire² multi-functional plate reader. To each sample 100 µl of MycoAlertTM Plus Substrate was 
added and incubated for 10 min at room temperature. Subsequently, the luminescence was 
determined again and the ratio between the values obtained from the first and from the second 
read was calculated. If mycoplasmal enzymes are not present, this ratio equals to one.  
 
1.1.4. Cryopreservation 
After successful generation and negative tests for mycoplasma infections LCLs were stored as 
cryopreserved aliquots until needed for experiments. Cell density was determined and cells were 
transferred in a 15ml Falcon tube in the desired number (usually between 1x106 and 1x107 cells) 
and centrifuged at 300 x g. The pellet was washed with preheated PBS (phosphate buffered saline), 
resuspended in 1ml of a preheated mixture of FCS and DMSO (9:1). DMSO is a cryoprotective 
additive reducing the formation of ice crystals which would destroy the cell membranes during the 
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freezing process. After transfer of the cell suspension into a cryotube, they were put immediately 
into a Mr. Frosty™ Freezing Container filled with ice-cold isopropyl alcohol and stored in a -80°C 
freezer for one day. Subsequently, the cryotubes were transferred to a liquid nitrogen container for 
long-term storage. 
 
1.1.5. Cell Counting 
From the appropriate cell suspension, 10 µl were transferred to a 0.5ml reaction tube and mixed 
with 10 µl of trypan blue solution. Trypan blue is a diazo dye used to distinguish living cells from 
dead cells through permeability differences (dead cells are stained due to decreased cell membrane 
integrity). After careful mixing, cell counts were determined using TC20™ Automated Cell Counter. 
Growth curves were generated by cumulative population doubling level (CPDL) method according 
to the following formula 145: 
 
  . 
 
1.1.6. Cultivation 
All cell culture work was carried out under aseptic conditions using laminar flow. All applied media 
and solutions were preheated to 37°C bevor contact with cells. FCS was heat-inactivated (30min, 
56°C) and stored in aliquots at -20°C. LCLs were cultured in RPMI medium supplemented with 15% 
heat-inactivated FCS, antibiotics (100 µg/ml penicillin, 100 µg/ml streptomycin) and a final 
concentration of 4 mM L-glutamine for at least two weeks before experiments were carried out. 
Culture media were stored at 4°C. To re-culture cryopreserved cells, one aliquot was rapidly thawed 
at 37°C and transferred to 9 ml of preheated medium in a 15ml Falcon Tube and then centrifuged 
at 300 x g for 3 min. Medium exchanging was done three times a week. Cells were incubated at 
37°C in a humidified CO2 incubator (with 5% CO2) in cell culture flasks (either T25 or T75) in upright 
position and used within two months from thawing.  
 
1.1.7. Treatment with Antidepressants 
LCLs were treated with different concentrations of SSRI antidepressant drugs for up to three weeks 
in T25 cell culture flasks. Stock solutions containing fluoxetine or citalopram were prepared in 
Nf… final cell number 
𝐶𝑃𝐷𝐿 =  ∑
ln
 𝑁𝑓
𝑁𝑖
⁄
ln 2
 Ni… initial cell number 
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DMSO at a concentration of 0.25 mg/ml and were stored as 1.5ml aliquots in glass vials at -20°C. 
Prior to use, stock solutions were sterile filtered by using a DMSO safe 0.2 µm nylon membrane 
syringe filter, a 1.5 ml syringe and a cannula. Cell culture media containing antidepressants were 
always freshly prepared before adding to the cells. Cells were treated with antidepressants while 
MOCK treated control cultures were grown in parallel. Every second day cell density was 
determined and set to 3x105 cells per milliliter.  
 
1.2. Determination of Proliferation Rates 
To determine individual proliferation rates, 5-ethynyl-2´-deoxyuridine (EdU) incorporation assays 
(Life technologies) were used. Experiments were carried out after continuous incubation with 
antidepressants for a maximum of three weeks. Cells were treated with a final concentration of 10 
µM EdU for two hours and detection of EdU incorporation was performed according to the 
manufacturer’s protocol using a FACS Calibur flow cytometer. EdU is a nucleoside analog to 
thymidine which is incorporated into newly synthesized DNA strands. Due to an artificial ethynyl 
moiety, a fluorescence dye (Alexa Fluor® 647) can be attached in a click reaction 146, 147, where the 
alkyne group of the EdU compound reacts in a copper catalyzed manner with the azide group of the 
fluorescence dye to a stable triazole (Figure 2, A). The fluorescence intensity of each cell can be 
determined by basic flow cytometry methods (Figure 2, B and C).  
 
 
Figure 2: Basic principle of the EdU proliferation assay. In a copper catalyzed reaction, a fluorescence dye is attached to 
newly synthesized DNA strands. Modified according to Invitrogen Handbook 
148
 (A). Fluorescence intensity is measured 
by flow cytometry (B). Discrimination of proliferating and non-proliferating cells by fluorescence analysis (C).  
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EdU-Workflow 
Sample preparation was done according to the manufacturer instructions in technical and biological 
duplicates. Cultured cells were transferred from cell culture flasks into cell culture multi-well plates 
and incubated with EdU solution at a final concentration of 10 µM for two hours (37°C, 5% CO2). 
Afterwards, cells were harvested by centrifugation (5 min, 7000 rpm) and the pellet was washed 
once with 750 µl of BSA (bovine serum albumin) solution (1% w/v in PBS). Cells were fixed by 25 µl 
of Click-iT® fixative containing paraformaldehyde for 15 min under light-free conditions followed by 
a further washing step with 900 µl of BSA solution (1% w/v in PBS). Before cell staining with 250 µl 
Click-iT® reaction cocktail (218.75 µl PBS, 5 µl CuSO4, 25 µl reaction buffer additive, 1.25 µl Alexa 
Fluor® 647 fluorescence dye azide) for 45 min under light-free conditions, they were permeabilized 
through 100 µl Click-iT® saponin-based permeabilization and wash reagent. After a final washing 
step, cell pellets were resuspended in 600 µl Click-iT® saponin-based permeabilization and wash 
reagent and analyzed by flow cytometry.  
  
Flow Cytometry Measurements 
Cellular fluorescence was measured by FACS Calibur flow cytometer. Gates were set to exclude 
both cell debris and cell aggregates. Measurements were performed until 10,000 events were 
reported. The detector parameters are shown in Table 3, primary threshold was channel FL2 with a 
value of 21. No secondary threshold or compensation was applied. Data analyses were performed 
using CellQuest Pro software. 
 
Table 3: Detector parameters of the FACS Calibur flow cytometer measurements of the EdU proliferation assays. 
parameter Voltage AmpGain Mode 
forward scatter E-1 3.52 Linear 
sideward scatter 300 1.10 Linear 
fluorescence channel FL1 670 1.00 Logarithmic 
fluorescence channel FL2 366 1.49 Linear 
   fluorescence channel FL2 - Amplitude - 1.00 Linear 
   fluorescence channel FL2 - Width - 1.00 Linear 
fluorescence channel FL3 650 1.00 Logarithmic 
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1.3. Gene Expression Analyses 
 
1.3.1. RNA extraction 
Cells were pelleted and resuspended in 350 µl lysis buffer (containing 1% v/v -mercaptoethanol). 
Prior to nucleic acid extraction, cell lysates were homogenized via QiaShredder to reduce viscosity 
and to remove insoluble material. RNA was extracted using the NucleoSpin® RNA Kit according to 
the manufacturer instructions. After addition of 350 µl of 70% ethanol to the lysate, the sample was 
transferred to an RNeasy Mini spin column and centrifuged for 15 s at 13,000 x g. RNA was washed 
once with 700 µl Buffer RW1, twice with Buffer RPE, dried through centrifugation (2min, 13,000 x g) 
and eluted in 30 µl RNase free water. Nucleic acid concentrations were quantified using a 
NanoDrop® Spectrophotometer.  
 
1.3.2. Synthesis of Complementary DNA  
From 1 µg of RNA, cDNA was prepared using Transcriptor First Strand cDNA Synthesis Kit in a 
thermal cycler over three steps (25°C for 10 min, 55°C for 30 min, 85°C for 5 min). RNA 
concentrations were adjusted to 100 ng/ml using RNase free water in a volume of 10 µl followed by 
addition of 30 µl of Mastermix (12 µl ddH2O, 8 µl transcriptase buffer, 4 µl random hexamer primer, 
4 µl dNTPs, 1 µl protector RNase inhibitor, 1 µl reverse transcriptase). PCRs (polymerase chain 
reactions) were carried out in a 0.2 ml collection tube and a total reaction volume of 40 µl. 
 
1.3.3. Primer Design and Validation 
Primers for desired nucleotide sequences were designed using the Primer-BLAST primer design tool 
(design parameters are shown in Table 4). Suggested primer pairs were checked for salt-adjusted 
melting temperature as well as potential formation of secondary structures and gene specificity 
using Oligonucleotide Properties Calculator 149 and UCSC Genome Bioinformatics BLAT alignment 
tool 150, respectively. Custom made, lyophilized primers were purchased from Eurofins Genomics 
(Ebersberg, Germany) and rehydrated in RNase free water to a concentration of 100 µM. Primers 
were validated by RT-PCR including evaluation of specificity through melting curve analysis (Figure 
3, A). Afterwards, PCR products (5 µl mixed with 1 µl of 6x loading dye) were separated by agarose 
gel (1%) electrophoresis for 45 min at 100 V (Figure 3, B). As a standard GeneRuler 50 bp DNA 
Ladder was used. Detection was performed after 30min incubation in ethidium bromide solution 
(200 ml TAE buffer with 2 µg/ml ethidium bromide) in a chemiluminescence detection system using 
Diana Software.  
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Table 4: Design parameters and specifications for custom made primers. 
Design parameter specification 
PCR product size 150nt -250nt 
primer melting temperature 58-60°C 
Maximum Tm difference 1°C 
intron inclusion yes 
intron length range 1,000nt - 1,000,000nt 
organism Homo sapiens 
Tm - melting temperature, nt - nucleotides 
 
 
 
Figure 3: Validation of custom-made primers was performed via melting curve analyse (A) and agarose gel 
electrophoresis (B). 
 
1.3.4. Quantitative Real-Time Polymerase Chain Reaction 
Real-time PCR experiments were conducted using QuantiTect SYBR Green PCR Kit. QuantiTect and 
primers were purchased from Qiagen (Hilden, Germany) (Table 5). 
Experiments were carried out using white 96-well plates in a LightCycler® 480 II system in technical 
and biological duplicates. After addition of 17 µl Mastermix (consisting of 55 µl ddH2O, 40 µl cDNA, 
125 µl SYBR green Mastermix) to each well, 3 µl of primer solution was given to each well. Cycle 
conditions are shown in Table 6. Data was analyzed using LightCycler® 480 Software Version 
1.5.1.62 SP2. Basal gene expression was indicated as CT values. Gene expression fold change (FC) 
was calculated by CT method using GAPDH as reference gene 151. 
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Table 5: Primers used for RT-PCR experiments. 
gene full gene name assay name or sequence 
ABCB1 
ATP-binding cassette sub-family B 
member 1 (P-glycoprotein) 
Hs_ABCB1_1_SG 
ABCG4 
ATP-binding cassette sub-family G 
member 4 
Fwd: CCTGGAGTTCAGGAACCAAC 
Rev: GTGAAGATGCCAGCATGGAG 
BTC betacellulin Hs_BTC_1_SG 
CACNA2D3 
calcium channel, voltage-dependent, 
alpha 2/delta subunit 3 
Hs_CACNA2D3_1_SG 
CYP3A43 cytochrome P450 3A43 HS_CYP3A43_1_SG 
EGFR epidermal growth factor receptor Hs_EGFR_vb.1_SG 
ERBB3 epidermal growth factor receptor 3 Hs_ERBB3_vb.1_SG 
FZD7 frizzled homolog 7 
Fwd: CCTTCCCCTTCTCATGCCC 
Rev: CAGCCCGACAGGAAGATGAT 
GAPDH 
Glyceraldehyde 3-phosphate 
dehydrogenase 
Hs_CACNA2D3_1_SG 
HBEGF heparin-binding EGF-like growth factor HS_HBEGF_1_SG 
KI67 Marker of proliferation Ki-67 
Fwd: AGGGAAAGGAGAAGCAGGAAATTCAGAC 
Rev: GAGGACATAGGCAAACAAACGACGACA 
MAPK9 mitogen-activated protein kinase 9 Hs_MAPK9_va.1_SG 
PIK3R5 
phosphoinositide-3-kinase, regulatory 
subunit 5 
HS_PIK3R5_1_SG 
SULT4A1 sulfotransferase family 4A, member 1 Hs_SULT4A1_1_SG 
TCF7 transcription factor 7 Hs_TCF7_va.1_SG 
TCF7L2 transcription factor 7-like 2 Hs_TCF7L2_1_SG 
WNT2B 
wingless-type MMTV integration site 
family, member 2B 
Hs_WNT2B_va.1_SG 
  fwd - forward, rev - reverse 
 
Table 6: RT-PCR cycle conditions. 
cycle numbers temperature duration 
1 95°C 10min 
60 
95°C 10s 
58°C 15s 
72°C 20s 
1 4°C - 
 
 
1.3.5. Determination of RNA quality  
Since degraded RNA affects down-stream experiments such as gene expression analysis, prior to 
microarray experiments the quality of RNA was evaluated using the Agilent 2100 Bioanalyzer 
system. This is a high sensitive standard method to assess RNA integrity and ribosomal ratios using 
electrophoretic separation of the samples and fluorescence based detection. With proceeding 
degradation of the RNA, the ratio between 18S and 28S ribosomal subunits band intensity 
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decreases. The Bioanalyzer software generates gel-like images and electropherograms (Figure 4) 
and calculates the RNA integrity number (RIN) - a standardized, user-independent scale reaching 
from values 1 (most degraded RNA) to 10 (most intact RNA) 152.  
 
 
Figure 4: Gel-like images (A) and electropherogram (B) of a successful Bioanalyzer run. The bands and peaks of the 
ribosomal 18S and 28S compounds are clearly visible. Impurities would generate additional signals. Only RNA samples 
with high purity were used for further experiments. 
 
Workflow 
First, the gel and gel-dye mix were prepared: After placing 550 µl of Agilent RNA 6000 Nano gel 
matrix in a spin filter, the filter was centrifuged for 10min at 1500 x g. To a 65 µl aliquot of filtered 
gel, 1 µl of RNA 6000 Nano dye concentrate was added and centrifuged for 10min at 13,000 x g. 
After transferring 9 µl of the gel-dye mix to the chip, 5 µl of markers as well as 1 µl of heat-
inactivated (70°C, 2 min) samples and RNA 6000 Nano ladder solution were pipetted into the 
particular wells. Measurement of the chips was done using the Agilent 2100 Bioanalyzer 
instrument. Data analysis was performed using Agilent 2100 Bioanalyzer Expert Software. Only RNA 
samples with RIN values larger than eight were used for subsequent down-stream experiments. 
 
1.3.6. Genome-wide Gene Expression Profiling 
A microarray-based gene expression analysis allows simultaneous quantification of gene products. 
Here, the SurePrint G3 Human Gene Expression 8x60K Microarray Kit (Agilent One Color Microarray 
Technology) containing more than 27,000 biological features was used. A feature consists of 
picomoles of immobilized probes which are gene specific DNA sequences. After fluorescence 
labeling of sample cRNA (complementary to probes) and probe-target-hybridization, fluorescence 
intensity as a measure of gene product amounts is determined, followed by gene chip quality 
control and data analysis.  
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Workflow 
After positive evaluation of RNA quality, microarray analyses were performed in ten cell lines 
(untreated and after 21 days of incubation with 0.5 µg/ml fluoxetine) according to the 
manufacturer’s instructions. A total of 100 ng mRNA extracted from LCL cell cultures was used for 
reverse transcription and labelling. The generation of cDNA was conducted with T7 promoter 
primers and AffinityScript reverse transcriptase in a total reaction volume of 10 µl incubating for 
two hours at 40°C followed by 15 min at 70°C. Fluorescence labelling was performed for two hours 
at 40°C after addition of NTP mix, T7 RNA polymerase and cyanin-3-cytidine triphosphate (CY3). 
After column-based purification of CY3-labelled cRNA, 600ng of CY3-labelled cRNA (specific activity 
>10.0 pmol Cy3/µg cRNA) was fragmented at 60°C for 30 minutes in a reaction volume of 25 µl 
containing 1x Agilent fragmentation buffer and 2x Agilent blocking agent. On completion of the 
fragmentation reaction, 25 µl of 2x Agilent hybridization buffer was added to the fragmentation 
mixture and hybridized to the microarrays slides for 17 hours at 65°C in a rotating hybridization 
oven. Subsequently, microarrays were washed 1 min at room temperature with GE Wash Buffer 1 
(Agilent) and 1 min with 37°C GE Wash buffer 2 (Agilent), then dried immediately by brief 
centrifugation. Fluorescence intensities were measured by SureScan Microarray Scanner after a 
final washing step to remove non-specific bound cRNA.  
 
Quality Control and Data Analysis 
Quality control was performed using Feature Extraction V 10 Software and included analysis of 
various physical quality parameters such as spike-in signals, outlier analysis, spot finding algorithms 
or spatial distribution of signals. Further, features with low-intensity or poor quality were removed. 
Data analysis was conducted using GeneSpring (Agilent) and data pre-processing includes 
normalization, flagging and filtering. After background subtraction and determination of raw spot 
intensities, normalization was performed using the multiaverage method which is necessary to 
adjust data sets for technical variations such as efficacy of dye incorporation, heat and light 
exposition, hybridization conditions and scanning conditions. Thus, relative abundance is reduced 
focusing exclusively on biologically relevant changes. To reduce artifacts, signal intensities below a 
defined cut-off point were removed from the dataset. The probeset was filtered on data files 
(control type 0) with the condition that at least 100% of the values in any one out of one condition 
are within the range.  
Pathway analyses identify specific gene networks affected by in vitro treatment relative to 
untreated controls. Single experiment pathway analysis was performed using the imported 
pathway database from GenMAPP Pathway Markup Language and 0.05 as an uncorrected p-value 
cut-off. Hierarchical cluster analysis is a technique grouping samples and genes with similar 
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expression patterns. Non-significant genes were removed by fold-change analysis. Differential gene 
expression was rated in pairs (treated vs. untreated) with a significance level of p<0.05 
(uncorrected) where value limits for under- and overexpressed genes were set to -2 and 2, 
respectively. To functionally characterize the remaining genes, gene ontology (GO) analyses and 
protein interaction analyses were carried out using the web-based STRING (Search Tool for the 
Retrieval of Interacting Genes/Proteins) database 153. A GO study extracts information about the 
biological function of a given gene set by identifying genes being involved in particular GO terms. 
Systematic search of CNS annotations were carried out using the gene names and one of the 
following terms: brain, neuron, neurogenesis, neural plasticity, proliferation, depression or 
antidepressant. 
 
1.4. Statistical Analyses 
Statistical analyses were carried out using IBM SPSS Statistics 21. All p-values are reported as 
nominal p-values and are unadjusted for multiples testing unless stated otherwise. In dependence 
of the nature of the data types either parametric (Student’s t-tests, Pearson correlation) or non-
parametric tests (Wilcoxon-Mann-Whitney rank-sum test, Spearman’s rank correlation) were used 
when analyzed with respect to the proliferation rates and gene expression data. To test for 
differences between antidepressant treated and untreated proliferation rates in the same cell lines 
the paired t-test was used. Between the groups of responders and non-responders the proliferation 
rates were compared with unpaired Student’s t-tests. To measure the strength of the relationship 
between the proliferation rates of different treated cells Pearson’s correlation coefficient () was 
calculated. Unpaired Student’s t-tests were used to analyze basal gene expression differences 
between non-proliferating and proliferating cell lines and to analyze basal gene expression 
differences between clinical subgroups (e.g. response after five and eight weeks and remission 
after five and eight weeks). Data of gene expression FCs was analyzed by Wilcoxon-Mann-Whitney 
rank-sum test. Associations between proliferation vs. age and proliferation vs. gender were 
calculated using Pearson’s correlation and Student’s t-test for equal variances (tested by Levene’s 
test), respectively. For all remaining applications, implemented statistic programs of the specific 
software (GeneSpring, STRING) were used. 
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2. Neuroimaging 
 
2.1. Clinical Study Design 
 
2.1.1. Overview 
This prospective, open label, non-randomized, single center, phase I trial was approved by the 
Federal Institute for Drugs and Medical Devices (BfArM) and the ethics commission of the Medical 
Faculty of the University Bonn. The full study’s title reads “Immune- and miRNA-response to 
recombinant interferon beta in healthy volunteers and patients with relapsing remitting multiple 
sclerosis” (trial short title: RESI) and is listed under EudraCT-number “2012-005475-13” in the EU 
Clinical Trials Register database. Before and after a nine-day standard therapy with recombinant 
interferon beta, psychometric testing as well as MRI measurements were conducted. A total 
number of 17 healthy volunteers were enrolled in this study. The trial was conducted at the 
dedicated phase I unit of the clinical study center of the university hospital Bonn in accordance with 
the ICH Guideline for Good Clinical Practice, the relevant national regulations and the Declaration 
of Helsinki.  
 
 
Figure 5: Overview of the study procedure. Before and after a nine-day standard therapy with interferon beta, 
psychometric testing as well as MRI measurements were performed.  
 
2.1.2. Participants 
Participants were healthy volunteers between 18 and 65 years who were recruited by the Clinical 
Study Center of the University Hospital in Bonn, Germany. Inclusion criteria were adequate function 
of liver (bilirubin, alanine transaminase, aspartate transaminase), kidney (creatinine), thyroid gland 
(thyroid-stimulating hormone), bone marrow (white blood cells, granulocytes, platelets, 
hemoglobin) and blood clotting (prothrombin time, partial thromboplastin time). Additionally, 
females needed to obtain a negative serum pregnancy test prior to treatment start and were 
instructed to use an approved contraceptive method (Pearl index < 1%) during and for 3 months 
after the trial. Exclusion criteria were abuse of alcohol, drugs or medication as well as a present co-
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medication with corticosteroids and a pronounced fear of blood drawings. Furthermore, potential 
subjects with a known allergy/hypersensitivity to interferon beta or any other ingredient of the 
injection solution, a history of malignant, cardiac, psychiatric disorders (including suicidal behavior) 
and particular infective diseases (e.g. acquired immunodeficiency syndrome, Hepatitis B or C) were 
excluded from this study. MRI-specific exclusion criteria were metal implants (e.g. pacemaker, 
inner-ear prosthesis, nerve stimulator, implanted defibrillator, infusion pump, artificial joints), 
magnetic or metallic objects that cannot be removed from the body (e.g. body piercing, dental 
prosthesis, implanted electrodes, contraceptive coil, acupuncture needle), claustrophobia, 
persistent tinnitus and tattoos or permanent makeup of a particular size (more than 10% of the 
body surface). Participants were not allowed to take part in other clinical trials with therapeutic 
intervention during this trial or within one month before enrolment. Mental health was evaluated 
by Mini-international neuropsychiatric interview (MINI). Inclusion was performed after the subjects 
gave written informed consents.  
 
2.1.3. Investigational Medicinal Product 
Interferon beta-1a received its marketing authorization in Germany in 1998. Prefilled syringes 
containing 44 µg of interferon beta-1a (Rebif®, Merck) were subcutaneously injected by trained 
personnel on days 1, 3, 5 and 8. Other ingredients are mannitol, poloxamer 188, L-methionine, 
benzyl alcohol, sodium acetate, acetic acid, sodium hydroxide and aqua ad injectabilia. No dose 
adjustments are intended by the trial protocol. In case of severe side effects (e.g. fever, head and 
body aches or chills) concomitant medication was allowed after consultation with the attending 
physician. 
 
2.1.4. Psychiatric Evaluation 
To assess change of psychiatric parameters after treatment with Interferon beta, depression and 
anxiety symptoms were examined with HDRS and STAI (State-Trait Anxiety Inventory) 
questionnaires, respectively. The interview-based HDRS was firstly developed by Max Hamilton in 
1966 and consists of multiple items aiming on depression-specific psychological parameters. 
Otherwise, the STAI bases on a self-report consisting of 40 questions with a four-pointed scale and 
measures the two main forms of anxiety (current and general anxiety). Higher scores are positively 
associated with more severe levels of depression or anxiety in both questionnaires. Paired t-tests 
by SPSS12 were used to statistically evaluate pre/post-changes in psychometric parameters.  
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2.2. Magnetic Resonance Imaging 
 
2.2.1. Functional Principle 
MRI scanners are able to use strong, uniform magnetic fields and radio waves to produce images of 
the human brain. Since the human body is largely composed of water molecules, tissue specific 
differences in the magnetic moment of the proton spin can be used to generate contrast pictures. 
Functional MRI allows determining brain activity while doing different tasks. The brain activity can 
be measured by detecting changes associated with blood flow because neuronal activation and CBF 
are tightly connected (hemodynamic response). An activation of a particular brain area leads to an 
increased metabolic activity and oxygen consumption. In consequence, oxygenated hemoglobin 
decreases and a disproportionate increase in perfusion emerges that stays at constant levels for the 
duration of the stimulation. The change in signal magnitude of the magnetic properties can be 
detected by MRI. The underlying mechanism is called blood-oxygen-level dependent (BOLD) 
contrast which describes the proportion of hemoglobin magnetization (oxygenated hemoglobin is 
diamagnetic and deoxygenated hemoglobin is paramagnetic) in the magnetic field 154. The higher 
the magnetic field strength, the higher the observed BOLD contrast and the signal-to-noise ratio 155. 
The localization of activated brain areas is possible through modelling differences in the BOLD 
signal following the contrast between task execution and resting-state (control condition). 
Statistical modelling allows the processing of test statistics of these contrast effects in each voxel 
which can be visualized as statistical parametric maps. 
 
2.2.2. Paradigms 
To measure specific brain activation patterns of depression-associated areas, all individuals had 
completed two tasks in functional brain imaging. Different paradigms were used to cover both the 
reward system and brain circuits of emotion. To probe sensitivity to reward cues in the ventral 
striatum and brain stem, a paradigm was employed - based on the work of Knutson et al. 156 - in 
which participants could collect money at different amounts (high and low), anticipated by 
appropriate cues 157. Participants were instructed to view the images and to press a button with 
their thumbs depending on the horizontal position of an appearing dot on the screen (see Figure 6). 
The total scan length of this paradigm was 8:07 minutes. Each correct response was rewarded by 
appropriate monetary amounts (0.01 € or 0.20 €) and money was paid off in cash after the scan, if 
the total amount was over 20.00 € - ensuring a high motivational status of the volunteers (maximal 
reward: 20.37 €). 
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Figure 6: Principle of the “reward” paradigm. Subjects are instructed press the left or right button of the keypad 
depending on the horizontal position of an appearing dot on the screen. Correct responses were rewarded according to 
the displayed monetary value. According to Viviani et al. 
157
. 
 
To target the amygdala and to evaluate reactivity to emotional stimuli, blocks of faces displaying 
the emotion of anger, sadness and disgust were displayed in a passive exposure paradigm 158, 159. In 
alternation, blocks of faces and geometric forms were presented (Figure 7) resulting in a total scan 
length of 3:17 minutes. Social images were taken from a set of standardized facial expressions 
provided by the Swedish Karolinska Institute 160. 
 
 
Figure 7: Principle of the faces paradigm. Subjects are instructed to focus on the alternating appearing blocks of images 
consisting of emotional faces (stimulus condition) and neutral geometric forms (control condition) 
160
. 
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2.2.3. Data Acquisition 
Data were acquired on a Skyra 3T MRI scanner (Siemens Healthcare, Erlangen, GER) by trained 
personnel. Scan sequences were controlled by manufacturer’s software. To ensure safety, metal 
detector analyses were conducted prior to entering the scan room. Subject wellbeing was 
continuously monitored by video camera, intercom and manual alarm system during the scan. To 
avoid subject’s hearing damages, foam earplugs were applied. Subject head movements were 
restrained with foam padding inside the 32 channel head coil. Paradigm pictures were presented on 
a monitor located behind the scanner and were displayed to the subjects via mirrors. Task 
responses were recorded by a button-box.  
To determine the exact brain position, overview scans (Head Scout Localizer) were conducted at 
the beginning of the scan procedure. Functional scans were acquired by echo planar imaging (T2-
weighted gradient-echo). An overview on measurement parameters is given in Table 7. 
 
Table 7: Overview on fMRI measurement parameters 
parameter functional imaging additional information 
AutoAlign Head>Brain  
Concatenations 1 slice distribution over multiple measurements 
Distance factor 20% 
gap between single slices expressed as percentage of 
slice thickness 
Echo time 30 ms 
time between the radiofrequency pulse and MR signal 
sampling 
Filter none corrections for non-uniform receiver coil profiles 
Flip angle 90°  
FoV read 192 mm size of the spatial encoding area of the image 
FoV phase 100%  
Matrix size 64x64  
PAT off  
Phase encoding direction A>>P direction of the pulsed magnetic field gradient 
Phase oversampling 0% 
artifact reduction technique for field-of-view 
exceeding objects 
Repetition time 2460 ms time between excitations pulses 
Slices  30 number of recorded planar regions 
Slice thickness 2.5 mm  
Voxel size 3.0x3.0x2.5 parameter for spatial resolution 
FoV - field of view, PAT - parallel acquisition technique 
 
The measurement window of fMRI was adjusted to achieve maximal coverage of the brain 
including the regions of interest such as the amygdala and the ventral striatum (Figure 8). The 
tilting angle of the measurement window was adjusted to the interface between the fourth 
ventricle and the brain stem (blue line) for each individual participant ensuring a constant coverage 
of all relevant brain areas over the course of this study. 
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Figure 8: Orientation of the measurement window. The tilting angle is adjusted to the interface between the fourth 
ventricle and the brain stem (blue line) to achieve maximal coverage.  
 
2.2.4. Data Analysis 
The imaging data were analyzed using SPM12 software which is a collection of specialized statistical 
techniques for the examination of brain activity differences in fMRI 161. Images for each subject 
were preprocessed including realignment to correct for head motion, normalization into a standard 
stereotactic space of an anatomical reference (by transformation of the images through translation, 
rotation, scaling and nonlinear warping) to allow comparisons between different subjects and 
smoothing with an 8 mm Gaussian kernel to increase signal-to-noise ratio. Regressors for faces 
paradigm were “pictures vs. control” (geometrical forms) and for foraging paradigm were “cue high 
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vs. cue low”. Contrasts were embedded into a design matrix that generates linear models with 
parameter estimates to compare fMRI data before and after interferon therapy. Statistical analyses 
were based on classical T-statistics and include calculations on peak level, cluster level and set level 
with FDR (false discovery rate) adjusted p-values by usage of height and spatial extent thresholds. 
Set level inferences are based on activated brain regions, i.e. the number of connected clusters 
above the threshold and are usually more powerful compared to cluster level analyses 162. Cluster 
level inferences consider the spatial extent (i.e. the volume or the number of activated and 
connected voxels that comprise the subset) and the peak height of the cluster when calculating 
significance. They are more sensitive than set level analyses but at the expense of localizing power 
162. The peak inference only takes the maxima height of single voxels into account and therefore is 
the less powerful method to detect brain activation differences. The repeated testing of the model 
in each voxel is accounted for by a correction for the multiple testing. Subsequently, the obtained 
p-values are visualized as statistical parametric maps using a p-value threshold of 0.001.  
 
 
3. Software 
 
Bioanalyzer 2100 Expert Software Agilent (Santa Clara, CA, USA) 
CellQuest Pro BD Bioscience (Franklin Lakes, NJ, USA) 
Feature Extraction V 10 Software Agilent (Santa Clara, CA, USA) 
GeneSpring X12 Agilent (Santa Clara, CA, USA) 
MATLAB The MathWorks (Natick, MA, USA) 
Microsoft Office 2010 Microsoft Corporation (Redmond, WA, USA) 
MRI console software Siemens Healthcare (Erlangen, GER) 
LightCycler® 480 Software  Roche (Basel, CH)  
DIANA raytest GmbH (Straubenhardt, GER) 
Presentation Neurobehavioral Systems Inc. (Berkeley, CA, USA) 
Primer-BLAST design tool  NCBI (Rockville Pike, MD, USA) 
BLAT alignment tool  UCSC Genome Bioinformatics (Santa Cruz, CA, USA) 
Oligonucleotide Properties Calculator Northwestern University (Chicago, IL, USA) 
SPSS Statistics 21 IBM (Armonk, NY, USA) 
Statistical Parametric Mapping Karl Friston (University College London, GB) 
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Chapter IV - Results 
 
1. Identification of Potential Gene Expression Biomarkers for 
Antidepressant Response 
 
1.1. Results from the MARS Cohort 
 
The MARS study is a naturalistic clinical study on antidepressant drug response designed for 
pharmacogenetics analyses of antidepressant drug response biomarkers. LCLs were generated in a 
subset of patients from the MARS project and were used as model systems to study individual 
proliferation and gene expression between fluoxetine-treated and untreated samples aiming on the 
identification of potential biomarkers for the pre-treatment prediction of individual antidepressant 
drug effects (experimental overview in Figure 9). Initially, screening experiments were carried out 
to identify a suitable experimental setup and as prove of concept verification. Subsequently, 
microarray experiments were carried out to find potential gene expression biomarkers. 
Proliferation phenotyping experiments of 50 MARS cell lines were conducted contemporaneously 
to study the differences of antidepressant-induced changes in proliferation behavior between non-
responder and responder derived cell lines. Finally, results of both arms were combined in an edge-
group approach as a further validation method to reduce the amount of potential biomarkers for 
remaining validation experiments.  
 
1.1.1. Screening Experiments 
To identify the most suitable experimental setup and method for measurement of individual 
proliferation rates, screening experiments were carried out using ten LCLs (derived from n=6 
responders and n=4 non-responders representing the average patient population with different 
medication profiles) from MARS study and fluoxetine as indicator drug. During the long-term 
incubation with different concentrations (0.0, 0.1, 0.5, 10.0 µg/ml) of fluoxetine, cell counts were 
recorded (three times a week) as well as EdU proliferation assays (weekly) and MKI67 gene 
expression (end point measurements after 21 days of in-vitro treatment with fluoxetine). On this 
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occasion, significant proliferative effects were measurable after three weeks of in-vitro treatment 
with therapeutical concentrations of fluoxetine using the EdU assay (Figure 10, A). Between treated 
and untreated samples no significant differences were detectable by cell counting (Figure 10, B). 
Very small significant effects were observable by KI67 gene expression analysis (Figure 10, C). 
 
 
Figure 9: Overview of the three phased project (screening, exploration and validation). After prove-of concept 
screening experiments which aimed on the identification of suitable experimental conditions, genome-wide gene 
expression and EdU phenotyping experiments were carried out to identify potential gene expression biomarkers and to 
explore the association between antidepressant induced LCL proliferation and donor’s clinical response status, 
respectively. Potential biomarkers were characterized in an edge-group approach followed by further RT-PCR 
validation experiments. 
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Figure 10: Result of the screening experiments using n=10 LCLs derived from the MARS study (values are indicated as means of these n=10 samples). Significant 
proliferative effects were observable by EdU proliferation assays after three weeks of incubation with fluoxetine but not after one or two weeks (A). No significant 
differences between treated and untreated samples were detectable via cell counting (B). Statistical but no biological significant effects (FC < 2) were reported through 
KI67 gene expression experiments (C). Statistical analyses included Student’s t tests with p-values: * < 0.05, ** < 0.01, *** < 0.001. 
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Detection of proliferation by EdU is the only method that directly measures proliferation and that 
allows a single cell evaluation. Individual differences between cell lines were detectable and most 
distinct proliferative effects occurred after three weeks of incubation with fluoxetine in 
therapeutical concentrations (0.1 µg/ml and 0.5 µg/ml) (Figure 11). Occasional proliferative effects 
were reported after one or two weeks of incubation with fluoxetine. Fluoxetine at a final 
concentration of 10.0 µg/ml show decreased proliferation rates in most of the cell lines. 
 
 
Figure 11: Heat-Map of EdU screening experiments. Ten cell lines were treated with different concentrations of 
fluoxetine over a time period of three weeks. After one, two and three weeks EdU proliferation assays were carried 
out. Different colors represent ranges of relative proliferation rates (ratio between fluoxetine treated and untreated 
controls of the same cell line): Reddish shades indicate a decreased proliferation and different green shades indicate an 
increase of relative proliferation rates; unchanged proliferation is indicated by black coloring. The occurrence 
frequency of each color (representing a defined range of relative proliferation) is shown in the bar graphs at the 
bottom of the figure. Strongest proliferative signals were detectable after three weeks of incubation with therapeutical 
concentrations of fluoxetine (0.1 µg/ml and 0.5 µg/ml). 
  
1.1.2. Proliferation Phenotyping 
To assess individual differences in cell proliferative effects of fluoxetine in LCLs from patients with 
documented clinical response status, we conducted long-term cell incubation with fluoxetine (21 
days) revealing a large variability in relative proliferation rates ranging from 54.7 to 155.2% in 
comparison to untreated cells from the same donor (Figure 12) indicating there are both pro- and 
anti-proliferative effects of fluoxetine in LCLs. Averaged over all 50 cell lines no significant overall 
effects were observable (100.00±0.0% control vs. 97.25±3.02; p=0.367). 
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Figure 12: EdU phenotyping of MARS cell lines. A total of n=50 cell lines (n=25 non-responder and n=25 responder derived cell lines) were treated for 21 days with therapeutical 
concentrations of fluoxetine (0.5 µg/ml). Proliferation rates were measured by EdU proliferation assay and are indicated as values relative to untreated control samples of the same 
cell lines (relative proliferation values of > 100% mean increased proliferation after fluoxetine treatment). Strong interindividual differences are detectable between the different cell 
lines ranging from 55% to 155% of relative proliferation rates.  
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Although there are inter-individual differences, when grouping the cell lines according to their 
clinical status no significant differences between the proliferation rates of the single groups (non-
responder vs. responder) were detectable (Figure 13, A). Basal proliferation, i.e. LCL proliferation 
without fluoxetine, is not associated with clinical response as well (Figure 13, B). 
 
 
Figure 13: Comparison of relative proliferation (after in-vitro treatment with fluoxetine relative to untreated samples 
from the same donor) between non-responder (n=25) and responder (n=25) derived LCLs (A) and between absolute, 
basal proliferation (untreated samples from the same donor) of non-responder (n=25) and responder (n=25) derived 
cell lines (B). Deviations are indicated as standard errors. No significant differences between responder and non-
responder derived cell lines are detectable. 
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Furthermore, we performed a trend analysis to identify a possible relation between individual 
response and individual LCL proliferation. No significant association was detected by Pearson’s 
correlation analysis (r=0.082, p=0.57) between proliferation rates and clinical response measured 
as percentage change in Hamilton-score compared between weeks 0 and 8 (Figure 14).  
 
 
Figure 14: Correlation plot between response factor and relative proliferation. The response factor is defined as 
percentage change in Hamilton scoring calculated for each participant between values at study inclusion (week 0) and 
at study end (week 8). Consequently, a cell line with a response factor > 50% is classified as responder. Individual 
relative LCL proliferation after three weeks of incubation with therapeutical concentrations of fluoxetine (0.5 µg/ml) is 
indicated as ratio to the untreated sample of the same cell line. By Pearson’s correlation analysis no association 
between response factor and relative proliferation is detectable (r=0.082 with p=0.57).  
 
The covariates gender (Figure 15, A) and age (Figure 15, B) showed no significant impact on 
individual proliferation rates by unpaired Student’s t-test (pgender=0.513) and Pearson’s correlation 
analysis (rage=0.071 with page=0.622). The same applies for donor’s underlying diseases, i.e. bipolar 
disorder, single episode major depressive disorders and recurrent major depressive disorders 
where no significant differences were detectable (Figure 16).  
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Figure 15: Analyses of the covariates gender (A) and age (B) and their impact on relative proliferation rates (after 21 
days of continuous treatment of n=50 LCLs with therapeutical concentrations of fluoxetine compared to untreated 
controls from the same cell lines). No significant impact of gender or age on relative proliferation rates was observable 
by Student’s t-test (pgender=0.513) or Pearson’s correlation analysis (rage=0.071 with page=0.622). Deviations are 
indicated as standard errors.  
 
Figure 16: Box plot of relative proliferation and donor’s underlying diseases indicated as International Statistical 
Classification (ICD) codes: F31.x - bipolar disorder (n=7); F32.x - single episode major depressive disorders (n=10); F33.x 
- recurrent major depressive disorders (n=33). No significant differences were detectable (p=0.799; p=0.237; p=0.889). 
Chapter IV - Results 
 
40 
1.1.3. Identification of Potential Gene Expression Markers 
The gene expression changes of n=10 LCLs (identical to those used in the screening experiments) 
was measured in a genome-wide approach to characterize gene expression changes by long-term 
fluoxetine and to identify potential gene expression biomarkers. Gene expression profiles were 
compared between untreated samples and samples treated for 21 days with 0.5 µg/ml of 
fluoxetine which is similar to the range in plasma concentrations in patients. Microarray data were 
deposited in NCBI’s Gene Expression Omnibus (GEO) database 163, 164 and are accessible through 
GEO Series accession number GSE83386. 
From 27,000 available genetic features, up to 15,241 were differentially regulated (FC > 2) in cell 
line 275U whereby only 3,501 genes were affected in cell line 278S indicating vast inter-individual 
differences in fluoxetine-induced gene expression profiles (Figure 17). Averaged over all ten cell 
lines they differentially expressed 7,715 ± 1,271 genes (FC > 2), 960 ± 164 genes (FC > 5) and 282 ± 
41 (FC > 10) genes. 
 
 
Figure 17: Quantities of differentially regulated genes (FC > 2, FC > 5 and FC > 10) in ten LCLs after three-week 
incubation with fluoxetine compared to untreated controls of the same samples and measuring gene expression 
profiles by Agilent microarray system with approximately 27,000 biological features. 
 
From this huge number of genes, potential genetic expression biomarkers, i.e. genes differentially 
regulated in non-responder and responder derived cell lines, need to be detected. To this end, 
various filtering techniques which are implemented in the microarray analysis software were 
applied (briefly summarized in Table 8 together with a short explanation of the techniques and the 
number of remaining genes after application of the appropriate filter) in order to successively 
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decrease the number of genes and therefore, to identify potential gene expression biomarkers. The 
results from each method will be described in detail in the following sections of this work. 
 
Table 8: Overview of different filtering methods for the identification of potential gene expression biomarkers out of 
the whole-genome gene expression data and their particular impact of remaining number of genes (n). 
filter technique Additional information n 
Cluster analysis 
Identification of cell lines clusters with different gene 
expression profiles (compared between untreated and 
fluoxetine-treated samples) 
3,501 - 15,241 
Pathway analysis 
Identification of pathways inversely regulated in NR and R 
derived indicator cell lines 
390 
Fold change analysis 
Filtering of genes obtained from pathway analysis according 
to their FCs after in-vitro treatment of the cell lines with 
fluoxetine 
127 
Gene ontology analysis Functional check point analysis 127 
NR/R-comparison 
Filtering of inversely regulated genes between NR and R 
derived cell lines 
15 
edge-group analysis 
Comparison of gene expression between cell lines with most 
distinct anti- and pro-proliferative effects from EdU 
phenotyping  
5 
NR - non-responder, R - responder 
 
The first method applied was a cluster analysis that aims on the identification of cell line clusters 
with different gene expression profiles compared between fluoxetine-treated and mock-treated 
samples of the same cell lines. Figure 18 shows the hierarchical clustering tree of the used cell lines 
that have been treated with fluoxetine for 21 days versus untreated control samples of the same 
cell lines. Except of cell lines 275U, 275J and 24DC, all samples of the same cell lines are located 
within the same cluster. This means these three cell lines showed great gene expression changes 
after in-vitro treatment with fluoxetine. The remaining cell lines (278S, 278D, 278H, 2411, 96, CY24 
and 1WXV) experienced no substantial differences in gene expression after fluoxetine incubation 
on gene cluster level. 
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Figure 18: Dendrogram of the hierarchical clustering analysis of the ten LCLs after three weeks of incubation with 
fluoxetine compared to untreated samples of the same cell lines. Up- and down-regulated genes are indicated by blue 
and red coloring, respectively. The most distinct changes in gene expression were recorded for the cell lines 275U, 275J 
and 24DC. 
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Secondly, a pathway analysis was carried out in three indicator cell lines (characterized by rectified 
clinical response status, experimental EdU proliferation status and hierarchical clustering status 
obtained from microarray experiments) to identify pathways that are involved in individual 
fluoxetine action and that possibly contain potential gene expression biomarkers. The pathway 
analysis revealed different amounts of significantly activated pathways by fluoxetine in the cell lines 
24DC (67 pathways), 275U (75 pathways) and 278H (42 pathways). Compared between responder 
and non-responder indicator cell lines (24DC and 275U vs. 278H), 14 inversely-regulated pathways 
were highlighted by Venn-analysis (Figure 19) that contain a total of 192 differentially expressed 
genes after incubation with fluoxetine (FC>2, p<0.05). The functions of this gene set were 
characterized by STRING-based GO analysis (Table 9). A total of 127 genes were reported to be 
involved in GO terms associated with brain remodeling processes such as neurogenesis (generation 
of neurons), axonogenesis (generation of axons), neuron differentiation (specialization of neural 
progenitor cells to neurons) or neuron projection (prolongation of nerve cells like axon or dendrite 
formation). 
 
Gene expression differences of these genes between non-responder and responder derived cell 
lines as measured by microarray experiments were evaluated. After consideration of individual cell 
line donor’s response status, 15 genes showed differences (FC difference > 2) in gene expression 
between responder (n=6) and non-responder (n=4) derived cell lines. The gene names, mean fold 
change differences as well as their annotated CNS functions are listed in Table 10. Gene expression 
differences between responder and non-responder fold changes by fluoxetine range from 40.3 for 
BTC to 2.0 for ERBB3 (epidermal growth factor receptor 3). All these genes can be assigned to 
either WNT signaling pathways (e.g. WNT2B, FZD7, TCF7L2) or EGF signaling pathways (e.g. BTC, 
EGFR, HBEGF) or to a group of pharmacokinetic genes (e.g. CYP3A43, SULT4A1, ABCB1, ABCG4). 
According to literature, most of these genes can be associated with brain-specific functions such as 
neuroplasticity, neural cell proliferation or stem cell regulation. Consequently, these genes were 
appointed as candidate gene expression biomarker genes and were used for further investigation. 
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Figure 19: Pathway analysis combined with Venn analysis revealed 14 pathways (yellow frame) differentially 
regulated between responder and non-responder indicator cell lines (24DC and 275U vs. 278H). Indicator cell lines 
are characterized by rectified LCL donor’s clinical response status, proliferation status and hierarchical clustering 
status. Due to different pathway versions with nearly identical pathways, only seven really different pathways 
remained (left column). P-values were calculated by GeneSpring X12 microarray software (Agilent) and are 
adjusted for multiple testing.  
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Table 9: Overview of the 30 most significant GO terms from the genes identified by Venn analysis. Brain and neuron 
specific GO terms are bold. P-values were calculated by STRING web-tool and indicated as uncorrected p-values and 
Benjamini-Hochberg corrected p-values (n is the number of identified genes being involved in particular GO terms).  
GO Term p-value corrected p-value n 
Neuron differentiation  
(GO:0030182) 
5.98e-27 7.54e-23 44 
Generation of neurons  
(GO:0048699) 
2.03e-25 8.22e-22 47 
Neuron projection development  
(GO:0031175) 
2.24e-25 8.22e-22 37 
Axon development 
(GO:0061564) 
3.00e-25 8.22e-22 34 
Response to chemicals  
(GO:0042221) 
3.26e-25 8.22e-22 76 
Cell development  
(GO:0048468) 
6.83e-25 1.43e-21 50 
Neuron projection morphogenesis  
(GO:0048812) 
1.08e-24 1.94e-21 34 
Cellular response to chemical stimulus 
(GO:0070887) 
1.47e-23 2.32e-20 57 
Axonogenesis  
(GO:0007409) 
1.91e-23 2.68e-20 32 
Positive regulation of signal transduction  
(GO:0009967) 
3.29e-23 4.14e-20 43 
Fc receptor signaling pathway  
(GO:0038093) 
6.87e-23 7.27e-20 27 
Neuron development  
(GO:0048666) 
6.92e-23 7.27e-20 37 
Cell projection morphogenesis  
(GO:0048858) 
8.93e-23 8.66e-20 35 
Canonical Wnt signaling pathway  
(GO:0060070) 
1.04e-22 9.41e-20 18 
Response to wounding  
(GO:0009611) 
1.51e-22 1.27e-19 42 
Positive regulation of signaling  
(GO:0023056) 
1.93e-22 1.52e-19 43 
Neurogenesis 
(GO:0022008) 
2.10e-22 1.53e-19 45 
Cell part morphogenesis  
(GO:0032990) 
2.18e-22 1.53e-19 35 
Cell morphogenesis  
(GO:0000902) 
1.27e-21 8.42e-19 37 
Regulation of signal transduction  
(GO:0009966) 
1.52e-21 9.079e-19 57 
Cell morphogenesis involved in neuron differentiation 
(GO:0048667) 
1.54e-21 9.079e-19 31 
Cell projection organization  
(GO:0030030) 
1.58e-21 9.079e-19 38 
Positive regulation of cell communication  
(GO:0010647) 
2.02e-21 1.11e-18 42 
Wound healing  
(GO:0042060) 
2.25e-21 1.18e-18 34 
Positive regulation of protein metabolic process  
(GO:0032270) 
2.45e-21 1.21e-18 41 
Cell morphogenesis involved in differentiation  
(GO:0000904) 
2.49e-21 1.21e-18 33 
Response to growth factor  
(GO:0070848) 
4.32e-21 2.02e-18 32 
Immune response-regulating cell surface receptors  
(GO:0002768) 
4.74e-21 2.12e-18 28 
Cellular response to organic substance  
(GO:0071310) 
4.88e-21 2.12e-18 49 
Regulation of signaling 
(GO:0023051) 
9.04e-21 3.80e-18 59 
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Table 10: Comparison of mean gene expression levels between responder and non-responder cell lines (n=10) and their 
annotated gene functions. Gene names are arranged by decreasing FC differences. CNS functions were systematically 
searched using the gene names and one of the following terms: brain, neuron, neurogenesis, neural plasticity, 
proliferation, depression or antidepressant. 
gene  
(Entrez ID) 
mean FC difference  
(Responder vs. Non-
Responder) 
CNS function 
 
BTC (685) 40.30 Stimulation of cell proliferation and neurogenesis 
165
 
WNT2B (7482) 26.20 Regulation of pro-neural genes 
166
 
EGFR (1956) 18.40 neural progenitor cells proliferation and migration 
167
 
CYP3A43 (64816) 6.90 antipsychotic metabolism 
168
 
PIK3R5 (23533) 6.70 risk factor for insomnia and suicides 
169-171
 
SULT4A1 (25830) 6.20 
brain-specific sulfate conjugation of drugs and 
neurotransmitters 
172
 
FZD7 (8324) 5.40 receptor for Wnt proteins in brain 
173
 
CACNA2D3 (55799) 5.30 possible role in long-term antidepressants action 
174
  
TCF7L2 (6934) 4.73 transcription factor in Wnt pathway 
173
 
ABCG4 (64137) 4.10 
regulation of lipid homeostasis in neurons and astrocytes 
175, 176
 
TCF7 (6932) 3.60 transcription factor in Wnt pathway 
173
 
HBEGF (1839) 3.50 Neurogenesis and astrocytes proliferation 
177
 
MAPK9 (5601) 2.50 mediates apoptosis in dopaminergic brain areas 
178
 
ABCB1 (5243) 2.45 export of neurotoxic agents in BBB 
179
 
ERBB3 (2065) 2.00 nervous system development 
180
 
 
 
 
To further characterize the candidate genes in an in-silico approach, possible interactions of these 
identified candidate genes were investigated: The prediction of protein interactions based on 
physical (direct) and functional (indirect) connections by STRING functional protein association’s 
network revealed some interactions between the 15 top-hit genes (Figure 20). As expected, the 
strongest interactions were observable for the proteins of the WNT and EGF pathways and 
interestingly, both of these pathways show interactions with each other as well (e.g. WNT2B with 
EGFR or TCF7L2 with ERBB3). No associations were detectable for SULT4A1, CYP3A43, ABCG4 and 
CACNA2D3.  
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Figure 20: STRING based protein interaction network of the 15 top-hit genes from microarray experiments after three 
weeks of incubation with therapeutical concentrations of fluoxetine. Network lines represent interactions between the 
proteins and the thicker the lines the stronger are the associations between the different gene products. The in-silico 
predictions of protein interactions such as physical or functional connections are based on scores from the STRING 
interaction database 
153
. 
  
To assess the potential of the identified candidate genes and their association with individual LCL 
proliferation after in-vitro treatment with fluoxetine, gene expression was analyzed in an edge-
group approach (in similarity to the work of Morag and colleagues 117). Both the basal gene 
expression and fluoxetine-induced changes in gene expression were compared between the two 
phenotypic edges of EdU phenotyping (five cell lines each) which is similar to those cell lines with 
the most distinct fluoxetine-induced anti-proliferative and pro-proliferative effects. Among the 15 
identified genes from the microarray experiments, the basal gene expression of four genes was 
significantly different from non-proliferator cell lines compared to proliferator cell lines: WNT2B 
(p=0.046), TCF7L2 (p=0.018), SULT4A1 (p=0.035) and ABCB1 (p=0.046) (Figure 21). After 
consideration of the clinical response status from the donors of these cell lines, no significant 
differences were detectable between LCL gene expression and donor’s clinical response and non-
response or between donor’s clinical remission and non-remission after five and eight weeks of 
antidepressant treatment during the MARS study (Figure 22). 
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Figure 21: Basal gene expression of the candidate genes in an edge-group analysis from EdU phenotyping experiments 
(proliferators vs. non-proliferators). Basal gene expression is indicated as CT values using GAPDH as reference gene. 
Significance was tested by unpaired Student’s t test.  
 
 
Additionally, fold change analyses were performed to characterize the effect of fluoxetine on the 
gene expression of the candidate gens. Results of the fold change analyses significantly correlated 
with in-vitro proliferation of genes WNT2B (p=0.032), TCF7L2 (p=0.008) and FZD7 (p=0.016) (Table 
11). The remaining genes showed no statistically significant effects of fluoxetine on gene expression 
levels between non-proliferator and proliferator cell lines. 
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Figure 22: Basal gene expression of the candidate genes in cell lines derived from donors with non-response or 
response after five (A) and eight weeks (B) and cell lines derived from donors with remission or non-remission after 
five (C) and eight weeks (D). Clinical improvement was rated after five and eight weeks by HDRS. No significant 
correlations between basal gene expressions of the candidate genes with clinical parameters of LCL donors were 
detectable. 
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Table 11: Fold change values of the candidate genes identified through microarray experiments after three weeks of in-vitro treatment with therapeutic concentrations of fluoxetine 
obtained in ten different LCLs in an edge-group approach after EdU phenotyping. Statistical analysis was carried out by Wilcoxon-Mann-Whitney rank-sum test and significant p-values 
are bold and underlined. 
 
Chapter IV - Results 
51 
Further validation of the candidate genes was performed: Changes in candidate gene expression 
were assessed after 21 days incubation with fluoxetine in all LCLs from EdU phenotyping 
experiments (n=50) limited to the five remaining genes showing significant differences in the EdU 
phenotyping edge-group approach. The associations between LCL gene expression and both the LCL 
donor’s remission and response status were investigated (Table 12). Basal gene expression of 
SULT4A1 correlated with donor’s clinical response after five weeks (p=0.029). However, basal gene 
expression of SULT4A1 was low and only detectable in 10 out of 50 cell lines (n=4 non-responder 
derived cell lines vs. n=6 responder derived cells). Furthermore, the gene expression fold changes 
of WNT2B after treatment with fluoxetine correlated with clinical remission status after five weeks 
(p=0.025). The remaining genes TCF7L2, FZD7 and ABCB1 showed no significant correlations with 
clinical parameters of LCL donors. 
 
Table 12: Statistical overview of LCL donor’s clinical outcome and LCL gene expression of the candidate genes in all 
tested MARS LCLs (n=50). Significant p-values are bold and underlined. Significance was calculated Student’s t test 
(basal gene expression) and Wilcoxon rank sum test (gene expression fold changes). 
 
 
WNT2B SULT4A1 TCF7L2 FZD7 ABCB1 
basal gene expression 
Response n.s. 0.029 n.s. n.s. n.s. 
Remission n.s. n.s. n.s. n.s. n.s. 
fold changes after in-vitro 
treatment with fluoxetine 
Response n.s. n.s. n.s. n.s. n.s. 
Remission 0.025 n.s. n.s. n.s. n.s. 
  n.s. - not significant 
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1.2. Results from the STAR*D Cohort 
 
STAR*D was an open label, randomized, multicenter, controlled clinical study aiming on the 
definition of effective subsequent treatment strategies after a first unsuccessful antidepressant 
therapy. All patients were treated with a citalopram monotherapy at the initial phase of this study. 
A total of 50 cell lines were obtained and were chosen to cover n=25 first-line therapy responders 
to citalopram and n=25 treatment resistant patients. Similar to previous experiments using LCLs 
from the MARS cohort, proliferation phenotyping was carried out after three weeks of in-vitro 
treatment with therapeutical concentrations of fluoxetine and citalopram. Additionally, the 
potential candidate gene expression biomarkers identified by microarray experiments of the MARS 
LCLs were further characterized and validated within this STAR*D cohort. 
 
1.2.1. Proliferation Phenotyping 
Individual variability of cell proliferative effects by SSRIs between n=50 STAR*D LCLs from various 
donors treated with citalopram monotherapy over the course of the STAR*D trial was assessed by 
EdU proliferation assays. After incubation of LCLs with therapeutic concentrations of citalopram or 
fluoxetine for three weeks, EdU-based proliferation phenotyping experiments revealed strong 
inter-individual differences between single cell lines (Figure 23). Both anti- and pro-proliferative 
effects were reported with relative proliferation rates ranging from 0% to 428%.  
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Figure 23: EdU phenotyping of STAR*D cell lines. A total of n=50 cell lines (n=25 treatment resistant and n=25 responder derived cell lines) were treated for 21 days with therapeutical 
concentrations of fluoxetine (0.5 µg/ml) or citalopram (0.3 µg/ml). Proliferation rates were measured by EdU proliferation assay and are indicated as values relative to untreated 
control samples of the same cell lines (relative proliferation values of >100% mean increased proliferation after fluoxetine treatment). Strong interindividual differences are detectable 
between the different cell lines ranging from 0% to 428% of relative proliferation rates. 
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Averaged over all n=50 cell lines, significant overall proliferative effects were reported compared to 
MOCK treated controls (Figure 24). By definition control was set to 100% and fluoxetine and 
citalopram treated LCLs achieved mean relative proliferation rates of 130.34±10.45 (p=0.006) and 
127.59±12.04 (p=0.026), respectively. Furthermore, a significant correlation between the fluoxetine 
and citalopram (both SSRIs) mediated proliferation rates was detected (=0.875, p<0.001) (Figure 
25). Basal proliferation, i.e. LCL proliferation without antidepressants, is not associated with LCL 
donor’s clinical response status (non-responder 17.44±1.83 vs. responder 15.92±2.13; p=0.591). 
 
 
Figure 24: Overall proliferative effects of fluoxetine and citalopram after three weeks of in-vitro treatment in 
therapeutic concentrations (n=50). Significance was tested by paired Student’s t test (p-values: * < 0.05, ** < 0.01) and 
significantly increased relative proliferation rates were reported for both fluoxetine (p=0.006) and citalopram 
(p=0.026).  
 
 
Further, the association between relative LCL proliferation rates and LCL donor’s clinical response 
status was investigated (Figure 26). Responder derived cell lines showed significantly increased 
proliferation after in-vitro treatment with fluoxetine (p=0.001) and citalopram (p=0.001), whereas 
non-responder derived cell lines showed decreased proliferation with fluoxetine (p=0.374) and 
citalopram (p=0.028). The differences in proliferation rates between LCLs derived from first-line 
responder versus LCLs derived from treatment resistant patients were highly significant 
(pfluoxetine<0.001, pcitalopram<0.001). 
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Figure 25: Correlation plot of fluoxetine and citalopram induced relative proliferation after in-vitro treatment with the 
SSRI antidepressants in therapeutic concentrations for three weeks. A highly significant correlation was observable 
(=0.875, p<0.001) between fluoxetine induced LCL proliferation and citalopram induced LCL proliferation. 
 
 
Figure 26: Mean relative proliferation rates of non-responder and responder derived cell lines treated with fluoxetine 
or citalopram for 21 days. Proliferation rates were significantly increased in responder derived cell lines and decreased 
in non-responder derived cell lines treated with citalopram. Significant differences between responder and non-
responder derived cell lines were observable (deviations are indicated as standard error; p-values: * < 0.05, ** < 0.01, 
*** < 0.001). 
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The correlation between QIDS reduction (as degree of LCL donor’s clinical response) and the 
experimentally determined relative proliferation rates was analyzed by Pearson’s correlation 
analysis: A positive significant correlation between percentage QIDS reduction and proliferation 
was detected for both citalopram (=0.331, p=0.019) and fluoxetine (=0.387, p=0.006) treated cell 
lines (Figure 27). 
 
Figure 27: Correlation plots of QIDS reduction and fluoxetine (A) or citalopram (B) induced relative proliferation.  
 
The impact of covariates such as gender, age, citalopram dosage, menopausal status or anxiety 
status on relative proliferation rates was investigated. No significant associations were found for 
both gender (pFluoxetine=0.142, pCitalopram=0.052) and age (Fluoxetine=-0.802 with pFluoxetine=0,581; 
Citalopram=0.054 with pCitalopram=0.710) (Figure 28, A-D). The same applies for the menopausal status 
of participating female subjects (pFluoxetine=0.731, pCitalopram=0.416) (Figure 28, E) as well as the LCL 
donor’s occurrence of anxious or non-anxious types of depression during the STAR*D study 
(pFluoxetine=0.771, pCitalopram=0.330) (Figure 28, F). Further, the amount of citalopram, i.e. the 
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citalopram dosage the donors were treated with over the course of the STAR*D study showed no 
influence on relative proliferation rates (fluoxetine: p10mg=0.186, p20mg=0.180; citalopram: 
p10mg=0.061 , p20mg=0.165) (Figure 28, G). 
 
 
Figure 28: Covariates analysis. No significant associations were found for gender (A - fluoxetine, B - citalopram), age (C - 
fluoxetine, D - citalopram), menopausal status (E), anxiety status (F) or dosage (G) by particular statistical methods 
(Student’s t test and Pearson’s correlation analysis). 
Chapter IV - Results 
 
58 
1.2.2. Gene Expression Analyses of Candidate Genes 
Within the same cohort of n=50 STAR*D LCLs the gene expression of the five candidate genes 
(ABCB1, FZD7, TCF7L2, SULT4A1 and WNT2B) was measured - including basal gene expression and 
gene expression after three weeks of in-vitro treatment with therapeutical concentrations of 
fluoxetine and citalopram. Subsequently, the relationship between LCL donor’s clinical response 
status and the LCL gene expression status was investigated. The basal gene expression levels of 
both WNT2B and ABCB1 are significantly elevated in non-responder derived cell lines relative to 
responder derived cell lines. Significant associations between LCL donor’s clinical response and LCL 
basal gene expression of WNT2B (p=0.0001) and ABCB1 (p=0.009) but not for FZD7 (p=0.643), 
TCF7L2 (p=0.355) or SULT4A1 (p=0.943) could be found (Figure 29, A). Basal gene expression of 
SULT4A1 was low and only detectable in 11 out of 50 cell lines (n=5 non-responder derived cell 
lines vs. n=6 responder derived cells).  
The relationship between gene expression fold changes (after three weeks of in-vitro treatment 
with fluoxetine and citalopram) and LCL donor’s clinical response status was explored as well 
(Figure 29, B and C). The fold changes of WNT2B (pFluoxetine=0.046, pCitalopram=0.003), FZD7 
(pFluoxetine=0.003, pCitalopram=0.002) and ABCB1 (pFluoxetine=0.009, pCitalopram=0.010) showed significant 
associations with LCL donor’s clinical response status. No significant associations of gene expression 
fold changes of TCF7L2 (pFluoxetine=0.140, pCitalopram=0.369) and SULT4A1 (pFluoxetine=0.548, 
pCitalopram=0.413) with the LCL donor’s clinical response status were found. A correlation matrix for 
the fluoxetine and citalopram induced fold changes in gene expression is shown in Table 13. Gene 
expression changes by fluoxetine or citalopram significantly correlate within genes WNT2B 
(=0.752), TCF7L2 (=0.477), FZD7 (=0.501) and ABCB1 (=0.413) but not for SULT4A1 (=0.367). 
 
Table 13: Correlation matrix of fold changes by fluoxetine and citalopram. Indicated are the correlation coefficients 
calculated by Spearman’s correlation and their appropriate significance (p-values: * < 0.05, ** < 0.01, *** < 0.001; n.s. 
not significant).  
  Fold changes by Citalopram 
  WNT2B SULT4A1 TCF7L2 FZD7 ABCB1 
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WNT2B 0.752*** - - - - 
SULT4A1 - 0.367n.s. - - - 
TCF7L2 - - 0.477*** - - 
FZD7 - - - 0.501*** - 
ABCB1 - - - - 0.413** 
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Figure 29: Results of gene expression experiments of the candidate genes. Basal gene expression indicated as 
difference of maximal cycle number of RT-PCR experiments and CP values of untreated samples (A). Gene expression 
fold changes after 21-day in-vitro treatment of LCLs with fluoxetine (B) or citalopram (C) (deviations are indicated as 
standard error; p-values: * < 0.05, ** < 0.01, *** < 0.001).  
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2. Neuroimaging of Interferon-induced Depressive-like Behavior  
 
The RESI study is a prospective, open-label clinical study whose participants received a nine-day 
standard therapy with recombinant interferon beta. Participants of the RESI study were screened 
for depressive symptoms by psychometric testing. MRI methods were applied in order to find some 
evidence for the depression inducing side-effects of interferon beta and to characterize the 
particular individual variability. A modified CONSORT (Consolidated Standards of Reporting Trials) 
flow diagram is shown in Figure 30. A total of 18 healthy volunteers received interferon beta 
therapy. One participant discontinued intervention due to intolerable side effects (high fever, heavy 
pain and chills). The remaining study cohort consisted of n=7 men and n=10 women with an 
average age of 26.5 ± 4.9 years. 
 
 
Figure 30: Overview of the course of the study by CONSORT flow diagram. From 38 volunteers, 18 were allocated to 
intervention with interferon beta. A total of 20 volunteers were excluded because they either did not met inclusion 
criteria (e.g. normal inflammation parameters, adequate liver, kidney and bone marrow function) or declined to 
further participate in the study. One participant receded from the study due to severe side effects like high fever, 
heavy pain and chills. 
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2.1. Psychometric Testing 
To ascertain the impact of interferon beta mediated changes of psychiatric parameters, anxiety and 
depression symptoms were examined by the widely-used questionnaires STAI and HDRS, 
respectively. The STAI measures the two main forms of anxiety, namely current and general 
anxiety. In both parts of this questionnaire no statistical significant differences were observable 
(pcurrent=0.793 and pgeneral=0.351) before (baseline) and after (steady-state) the nine-day treatment 
of 17 volunteers with interferon beta (Figure 31, A). However, individual variability was detectable 
with increases, decreases or constant levels in STAI scoring being observable depending on the 
individual participant (Figure 31, B).  
 
 
Figure 31: Box plots of the current (left) and general (right) STAI anxiety scores before (baseline) and after (stead-state) 
the nine-day standard therapy with interferon beta (A). The line graphs illustrates the individual variability of the 
current (left) and general (right) STAI anxiety scoring of each single participant over the course of the nine-day 
standard treatment with interferon beta (B). 
 
In contrast, depression scores using HDRS almost exclusively showed increases over the time 
(Figure 32, A) and consequently, highly significant changes were observed from baseline to steady-
state with a resulting p-value of 0.003 (Figure 32, B).  
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Figure 32: Progress of HDRS scores before (baseline) and after (steady-state) treatment with interferon beta. A strong 
increase of Hamilton-Scores was reported for individual participants (A) and the total cohort (B). Thicker lines 
represent more individuals with identical, overlapping HDRS values. 
 
When analyzing the single items of the HDRS, it becomes obvious from which parameters these 
effects were brought from (Figure 33): Strongest impairments were reported in the single items 
concerning “psychomotor retardation” (e.g. slowness of thought or difficulty in concentration), 
“work & activities” (characterized by feelings of incapacity, fatigue or weakness), “insomnia” (early, 
middle or late over the night span), “gastrointestinal symptoms” (e.g. loss of appetite or loss of 
weight) and “somatic symptoms” (e.g. indigestion, diarrhea, stomach cramps, heaviness in limbs, 
loss of energy). Weaker effects but still of note were found for the items “anxiety” (e.g. subjective 
tension or irritability, worrying about minor matters), “genital symptoms” (e.g. menstrual 
disturbance, loss of libido) and “hypochondriasis” (characterized by increased self-absorption). 
Unexpected but of interest is that a decrease in parameters “agitation” (e.g. fidgetiness) and 
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“feelings of guilt” (e.g. self-reproaches) was reported. However, only 2 out of 17 participants 
complained about depressed mood and fortunately, no signs of suicidal behavior or suicidal 
ideation - neither before nor after study participation - were detectable. Taken together depressive 
symptoms in the strict sense were barely detected, but other depression-related symptoms were 
frequently recorded by usage of HDRS. 
 
2.2. Functional Magnetic Resonance Imaging 
 
All participants (n=17) were instructed to complete two tasks (see chapter 2.2.2) during the fMRI 
session before and after interferon beta administration to measure the specific brain activation 
patterns of depression-related area in the money-rewarding foraging paradigm and the passive 
exposure faces paradigm. 
 
2.2.1. Foraging 
A paradigm was employed in which participants could collect money at different amounts (0.01€ vs. 
0.20€) to probe the impact of interferon beta on the sensitivity to reward cues. Table 14 gives an 
overview on the statistical analyses of this paradigm on set level, cluster level and peak level (for 
explanation see chapter 2.2.4).  
In fMRI the activity of the ventral striatum decreases after the treatment with interferon beta in 
(interaction cue high vs. low x treatment: x, y, z -14, 0, 2, t = 4.13, p = 0.06, FDR cluster-level 
corrected). Figure 34 shows the brain mapping of this paradigm before (“control”) and after 
interferon treatment (“treatment”) as well as the interaction mode. The interaction mode 
statistically compares the effects of two conditions (here: before and after interferon 
administration) and constitutes the main result of such fMRI measurements (Figure 34).  
C
h
ap
te
r IV
 - R
esu
lts 
 6
4
 
 
 
Figure 33: Single-item-analysis of results obtained from HDRS scoring before (baseline) and after (steady-state) a nine-day standard therapy with interferon beta. 
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Table 14: Statistical report of the foraging paradigm measurements before and after interferon beta administration 
including results on set, cluster and peak level with an uncorrected p value cut-off of 0.001. 
set level cluster level peak level coordinates (mm) brain areas 
size p size p T p x y z  
60 0.419 39 0.042 6.50 3.66E-06 -46.5 8 -16 Temporal pole superior left 
  
99 0.003 6.03 8.67E-06 7.5 30.5 27.5 Cingulum anterior right 
  
306 0.000 5.91 1.10E-05 28.5 32 41 Frontal middle right 
    
5.23 4.09E-05 24 44 38 Frontal superior right 
    
4.43 2.11E-04 27 27.5 33.5 Frontal middle right 
  
54 0.020 5.53 2.29E-05 -43.5 -37 15.5 Temporal pole superior left 
    
4.35 2.50E-04 -51 -32.5 12.5 Frontal inferior triangularis left 
  
27 0.084 5.33 3.40E-05 -27 3.5 -23.5 Amygdala left 
  
13 0.218 5.29 3.64E-05 -30 11 12.5 Insula left 
  
27 0.084 5.08 5.62E-05 -58.5 6.5 11 Rolandic operculum left 
  
195 0.000 4.89 8.21E-05 -25.5 45.5 29 Frontal middle left 
    
4.76 1.06E-04 -27 36.5 36.5 Frontal superior left 
  
10 0.278 4.80 9.91E-05 1.5 17 57.5 Supplementary motor area right 
  
1 0.759 4.77 1.04E-04 -67.5 -16 30.5 Postcentral left 
  
20 0.131 4.71 1.17E-04 31.5 24.5 0.5 Insula right 
  
7 0.365 4.54 1.67E-04 9 -20.5 8 Thalamus right 
  
32 0.062 4.50 1.81E-04 12 26 39.5 Cingulum middle right 
  
6 0.403 4.48 1.88E-04 6 6.5 62 Supplementary motor area right 
  
3 0.564 4.48 1.90E-04 9 -37 41 Cingulum middle right 
  
4 0.500 4.43 2.09E-04 1.5 11 60.5 Supplementary motor area right 
  
10 0.278 4.32 2.64E-04 7.5 -11.5 2 Thalamus right 
  
3 0.564 4.30 2.77E-04 -37.5 -7 -16 Hippocampus left 
  
3 0.564 4.27 2.90E-04 -9 30.5 30.5 Frontal superior medial left 
  
11 0.256 4.22 3.27E-04 -37.5 -32.5 41 Postcentral left 
  
1 0.759 4.21 3.30E-04 -13.5 6.5 53 Frontal superior left 
  
1 0.759 4.18 3.50E-04 7.5 -20.5 26 not allocated 
  
10 0.278 4.18 3.54E-04 18 -16 51.5 not allocated 
  
4 0.500 4.17 3.58E-04 -40.5 12.5 -23.5 Temporal pole superior left 
  
7 0.365 4.14 3.86E-04 -7.5 24.5 38 Cingulum middle right 
  
3 0.564 4.14 3.86E-04 -27 27.5 -4 Insula left 
  
5 0.447 4.11 4.06E-04 19.5 20 51.5 Frontal superior right 
  
3 0.564 4.11 4.11E-04 37.5 44 14 Frontal middle right 
  
1 0.759 4.06 4.57E-04 -25.5 26 0.5 not allocated 
  
2 0.646 4.05 4.60E-04 -31.5 9.5 6.5 Putamen left 
  
1 0.759 4.05 4.65E-04 6 -17.5 26 not allocated 
  
3 0.564 4.01 5.04E-04 -18 3.5 62 Frontal superior left 
  
1 0.759 4.00 5.15E-04 16.5 23 42.5 Frontal superior right 
  
1 0.759 3.98 5.42E-04 -55.5 11 17 Frontal inferior operculum left 
  
2 0.646 3.97 5.45E-04 -64.5 -17.5 26 Postcentral left 
  
1 0.759 3.97 5.45E-04 -31.5 8 0.5 Putamen left 
  
1 0.759 3.97 5.51E-04 -4.5 -25 24.5 not allocated 
  
1 0.759 3.95 5.76E-04 -16.5 3.5 59 Frontal superior left 
  
1 0.759 3.94 5.89E-04 33 44 11 Frontal middle right 
  
1 0.759 3.92 6.06E-04 30 -2.5 -23.5 Amygdala right 
  
2 0.646 3.92 6.12E-04 40.5 44 15.5 Frontal middle right 
  
1 0.759 3.90 6.37E-04 4.5 -8.5 -1 Thalamus right 
  
1 0.759 3.90 6.39E-04 4.5 -17.5 30.5 Cingulum middle right 
  
1 0.759 3.88 6.68E-04 -9 32 8 not allocated 
  
1 0.759 3.86 6.90E-04 9 -31 42.5 Cingulum middle right 
  
2 0.646 3.84 7.22E-04 13.5 -65.5 26 Precuneus right 
  
1 0.759 3.84 7.24E-04 -13.5 32 35 Frontal superior medial left 
  
1 0.759 3.82 7.51E-04 -67.5 -29.5 32 Supra marginal left 
  
1 0.759 3.79 8.04E-04 12 21.5 38 Cingulum middle right 
  
1 0.759 3.76 8.53E-04 30 27.5 -10 Frontal inferior orbital right 
  
1 0.759 3.75 8.66E-04 -19.5 -68.5 51.5 Parietal superior left 
  
3 0.564 3.75 8.80E-04 -40.5 8 -26.5 Temporal pole superior left 
  
1 0.759 3.73 9.06E-04 -43.5 41 20 Frontal middle left 
  
1 0.759 3.73 9.07E-04 -10.5 -46 57.5 Precuneus left 
  
1 0.759 3.72 9.23E-04 18 23 48.5 Frontal superior right 
  
1 0.759 3.71 9.41E-04 -58.5 -31 12.5 Temporal superior left 
  
1 0.759 3.71 9,48E-04 10,5 -62,5 24,5 Precuneus right 
  
1 0,759 3.70 9,71E-04 -4,5 32 20 Cingulum anterior left 
  
1 0,759 3.70 9,74E-04 -66 -31 30,5 Supra marginal left 
  
1 0,759 3.69 9,85E-04 -67,5 -26,5 29 Supra marginal left 
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Figure 34: Results of the foraging paradigm indicate a lowered activity of the ventral striatum (blue circle) after 
interferon beta administration. The brain mapping shows activation patterns of this money-rewarding paradigm before 
(“control”) and after interferon treatment (“treatment”) as well as the interaction mode - a statistical comparison of 
the effects at the both mentioned time points. The slices are shown at y=+5mm and the key indicates the level of 
activation (T-values). 
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2.2.2. Faces 
Blocks of emotional faces were displayed in a passive exposure paradigm to target the amygdala 
and to evaluate the reactivity to emotional stimuli before and after interferon administration. Table 
15 gives an overview on the statistical analyses of this paradigm on set level, cluster level and peak 
level with no relevant activation differences in the amygdala. In general the amygdala was active at 
both time points (“control” and “treatment”, see upper part of Figure 35) which indicates the faces 
paradigm was successful in eliciting its activation but no significant changes in amygdala activation 
before and after interferon treatment were detectable as can be seen in the interaction mode of 
the particular brain mapping (Figure 35).  
  
Table 15: Statistical report of the faces paradigm measurements before and after interferon beta administration 
including results on set, cluster and peak level with an uncorrected p value cut-off of 0.001. 
set level cluster level peak level coordinates (mm) brain areals 
size p size p T p x y z  
32 0.200 91 0.003 5.36 3.219E-05 24 -30 32 not allocated 
  47 0.023 5.32 3.443E-05 38 6 20 Insula right 
    4.45 2.013E-04 32 14 26 not allocated 
    4.20 3.414E-04 36 6 28 Frontal inferior operculum right 
  20 0.117 4.90 8.043E-05 40 -52 -6 Temporal inferior right 
  19 0.126 4.68 1.264E-04 32 -24 -6 Hippocampus right 
    4.18 3.554E-04 38 -28 -10 Hippocampus right 
  8 0.312 4.62 1.410E-04 -26 -40 22 not allocated 
  10 0.259 4.50 1.808E-04 4 4 -28 not allocated 
  4 0.480 4.48 1.896E-04 26 -48 34 not allocated 
  7 0.345 4.47 1.946E-04 42 -44 20 not allocated 
  8 0.312 4.46 1.956E-04 34 -62 -4 not allocated 
  6 0.383 4.43 2.085E-04 20 26 32 Frontal superior right 
  4 0.480 4.32 2.641E-04 16 -10 20 Caudate right 
  1 0.748 4.29 2.806E-04 -20 -12 48 not allocated 
  1 0.748 4.22 3.256E-04 38 0 28 not allocated 
  2 0.630 4.20 3.388E-04 18 30 26 not allocated 
  1 0.748 4.10 4.217E-04 44 -34 2 Temporal middle right 
  1 0.748 4.09 4.252E-04 40 -28 -6 Hippocampus right 
  7 0.345 4.03 4.814E-04 -30 -60 10 not allocated 
  1 0.748 4.02 4.899E-04 18 22 32 not allocated 
  3 0.546 3.98 5.347E-04 -4 -26 68 Cingulum anterior left 
  2 0.630 3.96 5.635E-04 -40 -54 -4 Temporal middle left 
  1 0.748 3.95 5.767E-04 -14 8 36 not allocated 
  1 0.748 3.92 6.141E-04 34 20 20 not allocated 
  1 0.748 3.90 6.396E-04 44 0 22 not allocated 
  2 0.630 3.88 6.587E-04 -18 -14 46 not allocated 
  1 0.748 3.87 6.747E-04 0 28 -20 Frontal medial orbital right 
  1 0.748 3.85 7.077E-04 -46 -22 -16 Temporal middle left 
  2 0.630 3.84 7.164E-04 16 48 30 Frontal superior right 
  1 0.748 3.81 7.676E-04 34 -50 -6 Fusiform right 
  1 0.748 3.77 7.878E-04 -18 28 28 not allocated 
  1 0.748 3.77 8.440E-04 40 -42 4 not allocated 
  1 0.748 3.73 8.459E-04 18 26 36 Frontal superior right 
  1 0.748 3.73 9.019E-04 46 2 24 Precentral right 
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Figure 35: Results of the faces paradigm indicate no significant changes of the activity of the amygdala and the central 
nucleus region (blue arrows) after interferon beta administration. The slices are shown at y=-8mm and the key 
indicates the level of activation (T-values). 
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Chapter V - Discussion 
 
1. Previous Findings from MARS and STAR*D 
 
The cell lines utilized over the course of this work were derived from large clinical trials focusing on 
depressive disorders, namely the MARS and STAR*D studies. The MARS trial attempted to identify a 
biomarker portfolio for the prediction of the individual treatment guidance using transcriptomics, 
proteomics and metabolomics techniques as well as neuroendocrine testing and neuroimaging. 
More than 1,000 depressive patients took part in this naturalistic study showing response and 
remission rates of up to 80.8% and 57.9%, respectively 137. Polymorphisms within the FKBP5 (FK506 
Binding Protein 5; a glucocorticoid receptor involved in the regulation of the HPA axis) gene and an 
increased expression of FKBP5 significantly correlated with the relapse of depressive symptoms and 
with the remission 181. Furthermore, polymorphisms of other genes such as HTR2A (5-
hydroxytryptamine receptor 2A), ER22/23EK (glucocorticoid receptor), ABCB1 or GAD2 (glutamate 
decarboxylase 2) were identified as potential biomarkers for the treatment response and the 
susceptibility to develop depressions 182-189. Genetic variations of TPH2 (tryptophan dehydroxylase 
2) or NTRK2 (neurotrophic tyrosine kinase receptor type 2) were also linked to antidepressant’s side 
effects or suicidal behavior 190, 191. An increased cortical response was associated with the relapse of 
depressive symptoms after six months of remission renders it a potential biomarker to predict the 
clinical outcome 139, 140. In contrast a decreased reactivity to cortisol and adrenocorticotropin was 
associated with both suicidal ideation and suicide attempts 192. Behavioral testing was shown to be 
able to predict response to antidepressant treatment and the risk to relapse 193, 194. Furthermore, 
obese patients demonstrated minor neuroendocrinological changes accompanied by worse 
response relative to normal-weighted patients 195. 
The STAR*D trial was designed to ascertain which treatment strategy would be generalizable 
optimal by prospectively recording the therapy tolerability and outcome throughout up to four 
different defined treatment levels 196. A time period of over six years and more than 4,000 
depressive patients were making this study to one of the largest of its kind with total costs of $35 
million 197. In level one - where all patients were treated with citalopram for up to 14 weeks - an 
overall response rate of 47% and remission rates of approximately 30% were reported. Non-
remitters entered the subsequent levels until remission was achieved. Level two included seven 
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different treatment options in addition to citalopram (further antidepressants or psychotherapy) 
and level three consisted of a switch to another antidepressant (nortriptyline or mirtazapine with 
remission rates of 19.8% and 12.3%, respectively) or the addition of lithium as mood stabilizer. The 
fourth level included a combination therapy of mirtazapine and venlafaxine (average remission rate 
of 13%) or comedication with tranylcypromine 198, 199. The mean times to remission range from 5.4 
to 7.4 weeks between the different treatment levels 200 and the chances of remission were smaller 
with each failed treatment level pointing up to the importance of reliable predictive biomarkers 201. 
 
 
2. Lymphoblastoid Cell Lines in Pharmacogenomical Research 
 
Due to their wide availability from different individuals and their representation of individual 
donors properties, the applicability of LCLs in pharmacogenetics is emerging. They are suitable to 
cover various phenotypes like apoptosis, cell growth inhibition or gene expression 202, 203. In the past 
research with LCLs focused on pharmacogenetics of indications such as oncology 204, 205, cardiology 
206 or pulmonology 207. However, interest in research of psychological disorders using LCLs is rapidly 
growing. LCLs are generated through immortalization of easily obtainable PBMCs performed by EBV 
transfections 208, whereby these viruses specifically infect B-lymphocytes without integration of 
viral genes into the host genome but with maintenance as latent extrachromosomal episomes 209. 
EBV transformation modifies gene expression profiles as well as the methylation pattern of 
promotor regions in approximately 50% of all genes, but individual differences between cell lines 
remain intact 210. Additionally, LCLs seem to cover naturally occurring variations of the whole 
genome and epigenome 211. Because LCLs are long-living and can be stored as cryocultures and (re-
)cultivated under laboratory conditions, they basically are an infinite source of individual patient’s 
genetic material avoiding repeated resampling of blood samples which is an advantage for long-
termed studies aiming on personalized therapy 212. Consequently, as cell-based models they might 
help to support the identification of predictive biomarkers for various diseases. LCLs allow to cost-
effectively performing ex-vivo experiments under well-controlled conditions, i.e. without the 
impact of confounders such as concomitant medications, nutrition, smoking status, etc. 204. 
However, being derived from one single cell type and being only a cell-based model, LCLs do 
neither represent the complexity of the whole human organism nor completely reflect cellular 
proliferation or gene expression changes of multicellular tissues such as the brain. For instance, 
LCLs do barely express CYP (cytochrome P450) enzymes - relevant for the metabolism of various 
antidepressants, neurotransmitters and other neuroactive agents - making them unsuitable models 
for pharmacokinetic studies 205. One general concern is the transferability of results obtained from 
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LCLs into clinical practice which has so far for instance successfully been done in the indication of 
cancerous diseases 213-216 but not yet in psychiatry biomarker research. Although there is some 
evidence that LCLs do not faithfully represent pathological changes of psychiatric diseases 217, 
logically LCLs from patients should be given preference to LCLs from healthy donors when looking 
for disease-specific biomarkers - as done over the course of this work. Despite LCLs express more 
than 4,000 brain specific transcripts 120, it is unclear whether they are helpful to identify relevant 
gene expression changes of antidepressant response - especially due to the high heterogeneity of 
depressive disorders. Furthermore, the fact gene expression changes following drug exposure could 
be different in blood-derived cells in comparison to neural cells should find critical consideration as 
well as the circumstance that LCLs show different methylation signatures related to neurons which 
probably leads to epigenomic-mediated effects on transcription levels 218. Only a few studies so far 
employed LCLs as models for the investigation of individual antidepressant response. Here, LCLs 
were used to study individual proliferation and gene expression changes following antidepressant 
drug treatment. We found significant and large antidepressant-induced gene expression changes of 
neural and non-neural genes including high inter-individual differences as well as group differences 
between non-responder and responder derived LCLs. Several other observations support the 
potential role of LCLs as model for individual variability of drug effects in the CNS. In experiments 
from Morag and colleagues using LCLs from healthy donors, antidepressant induced growth 
inhibition was used as surrogate phenotype leading to the identification of neuronal genes such as 
CHL1 (close homologue of L1) through genome-wide gene expression profiling as top-hit gene with 
different basal expression levels between paroxetine sensitive and insensitive LCLs 117, 118. CHL1 
encodes for a neural cell adhesion protein involved in neurite outgrowth regulation, neural 
connectivity and thalamocortical circuity 219-223. Further, in addition to an implication in depression 
224, CHL1 plays a role in other neurological diseases such as schizophrenia and autism 225, 226. By 
usage of genome-wide gene expression profiling and genome-wide miRNA arrays after three weeks 
of in-vitro treatment with hyper-therapeutic concentrations of paroxetine, Oved et al. identified 
gene expression differences of ITGB3 (integrin beta-3) and miRNAs targeting ITGB3, respectively 227. 
They proposed that ITGB3 provides a missing link between CHL1 and SERT: ITGB3, as a known co-
activator for SERT, is necessary for the proper functioning of this transporter 228, whereby CHL1 
seems to reduce available ITGB3 molecules by high-affinity binding and therefore regulates SERT 
activity 227. SERT in turn, is the target of SSRI antidepressant drugs and increases the availability of 
serotonin within the synaptic cleft especially in pathways of the prefrontal cortex and the 
hypothalamus inducing the initial phase of remission from depression. The potential of CHL1 and 
ITGB3 as tentative gene expression biomarker was confirmed in subsequent studies using LCLs 
derived from depressed patients 119 and SNPs in neuronal cell adhesion genes involved in synaptic 
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plasticity were recently shown to affect treatment response in depressive disorders 229. Moreover, 
within a STAR*D cohort, CHL1 was nominated as a tentative SSRI sensitivity biomarkers implicated 
in adverse reactions of citalopram in combination therapy with buspirone 230. In the present work 
neither CHL1 nor ITGB3 were traceable as tentative gene expression biomarkers using genome-
wide gene expression profiling before and after the in-vitro treatment of patient-derived LCLs with 
SSRIs. In another study with LCLs, growth inhibition profiles were used to assign shared pathways 
following in-vitro treatment with different drug classes including antidepressants that can be used 
to categorize distinct pathways 231. In addition to these studies that focused on LCLs as tools for the 
identification of biomarkers for depressive disorders, a few studies explored the utility of LCLs in 
other psychological diseases such as bipolar disorders or autism 232-234. Consequently, all these 
findings point to the importance of LCLs in psychiatric pharmacogenomic research.  
 
 
3. Peripheral Proliferation as Surrogate Marker for Antidepressant 
Response 
 
In initial screening experiments using fluoxetine as indicator drug, several methods for the 
determination of individual prolferation as well as various drug concentrations and incubation 
times were compared in order to identify optimal experimental conditions. Fluoxetine was chosen 
as antidepressant drug because most of the MARS patients under antidepressant monotherapy 
received SSRI antidepressant drugs and the proliferative features of fluoxetine are well-studied 235-
241. Since antidepressants-mediated improvement of clinical symptoms usually appears with a delay 
of several weeks, LCLs were incubated with antidepressants for up to three weeks in different 
concentrations covering the therapeutical range of fluoxetine blood concentrations (0.1 µg/ml and 
0.5 µg/ml). Additionally, supra-therapeutical fluoxetine concentrations (10.0 µg/ml) were included 
as it was unclear in advance which amounts of fluoxetine will cause detectable proliferation effects 
(fluoxetine shares high protein binding properties and higher concentrations might be required in 
cell culture experiments) 242. However, no fluoxetine induced increases in cell proliferation were 
observable over the three week incubation period by cell counting and subsequent creation of 
growth curves. Chang et al. were able to detect significant effects after 15 days of incubation with 
fluoxetine - by application of the same experimental design (0.5 µg/ml fluoxetine dissolved in 
DMSO, change of culture medium every second day) and evaluation method as performed here 
(CPDL) - in adherently growing neural precursor cells derived from human embryonic stem cells 243. 
Gene expression analysis of MKI67 is a widely applied method for the quantification of proliferation 
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on a molecular level. MKI67 is a nuclear protein required for cell proliferation which is exclusively 
expressed in active phases of the cell cycle like G1, S and G2 244. Although interindividual 
differences were detectable as well as statistically significant increases in gene expression levels of 
MKI67 after chronic in vitro treatment with fluoxetine, no biological relevant effects were 
detectable. Biologically relevant in this context means an increase of fold changes to values larger 
than two 245. The EdU assay is the only method that directly measures proliferation allowing single 
cell evaluations. We reported significantly biological and statistical effects after three weeks of 
chronic exposure with concentrations of fluoxetine equal to therapeutic blood concentrations in 
fluoxetine-treated patients suffering from depression which is in accordance with the already 
described neurotrophic hypothesis of antidepressants action. Interestingly, higher concentrations 
of fluoxetine (10 µg/ml) already showed toxic or anti-proliferative effects. Toxic effects might be 
based on a genotoxic and mutagenic potential 246 and other studies reported fluoxetine-mediated 
cytotoxic effects 247-249. However, molecular mechanisms of fluoxetine-induced toxicity are unclear 
but might be based on the interruption of chromosal structures 250, the inhibition of metabolizing 
enzymes 251 or the interference with the energy metabolism 252. Since LCLs do not or barely express 
major phase one CYP enzymes relevant for antidepressant metabolism such as CYP2D6, CYP2C9, 
CYP2C19 or CYP3A5, observed effects assuredly are ascribable to fluoxetine and citalopram but not 
to their metabolites like norfluoxetine and demethylcitalopram, respectively 253, 254. 
Following the screening experiments and in search of tentative functional biomarkers for 
antidepressant response prediction, we tested fluoxetine effects on cell proliferation in LCLs from 
depressed patients participating in the MARS study. Individual effects on cell proliferation have 
been detected after 21 days of incubation with fluoxetine. Although the in vitro treatment of 
patient-derived LCLs with fluoxetine presents high inter-individual variability regarding the LCL 
proliferation behavior, this phenomenon has no association with the MARS patient’s clinical 
outcome. Both pro- and anti-proliferative effects were reported and averaged over all cell lines, no 
significant overall effects after in vitro treatment with fluoxetine were observable. Further, no 
significant associations between the individual basal proliferation rates, i.e. under control 
conditions without fluoxetine, were detectable. The relative proliferation after fluoxetine 
incubation relative to untreated controls from the same donors showed no significant association 
with LCL donor’s response or remission status as well. Additionally, the proliferation rates of 50 
LCLs derived from depressed patients participating in the STAR*D trial were determined after three 
weeks of incubation with therapeutical concentrations of the antidepressant drugs fluoxetine and 
citalopram. Here, we could show strong inter-individual differences between single cell lines as well 
as significant overall proliferative effects. The fluoxetine and citalopram (both SSRIs) mediated 
proliferation were highly correlated. Additionally, a direct association between peripheral in-vitro 
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proliferation rates of patient derived LCLs and clinical outcome in depression was shown: A 
significant correlation between percentage QIDS reduction, i.e. the improvement of clinical 
symptoms and LCLs proliferation rates was detected. Responder derived cell lines showed 
significantly increased proliferation after in vitro treatment with antidepressants compared to non-
responder derived cell lines.  
In cohorts from both antidepressant studies, no influence of general covariates like age or gender 
on proliferation rates was observable. These results are coherent with recent findings of Morag et 
al. who studied the influence of age and gender in antipsychotic drug sensitivities in human LCLs 255. 
The same applies for study specific covariates such as co-medication and individual’s underlying 
diseases (MARS) or citalopram dosage, menopausal or anxiety status (STAR*D). In contrast anxious 
depression was shown to be associated with decreased remission rates compared with outcomes 
from patients with non-anxious depression 256, 257. In general LCLs derived from the STAR*D study 
showed stronger antidepressant-mediated increases (up to 428%) of relative cellular proliferation 
rates compared to cell lines obtained from the MARS study (up to 155%) which might have several 
reasons. Firstly, extreme groups of clinical improvement from the STAR*D trial were used for 
proliferation phenotyping (cell lines from treatment resistant donors vs. cell lines from 
strongest/fastest responders). Secondly, LCL donors of STAR*D were treated with citalopram 
monotherapy whereas those from MARS were - due to the naturalistic study character - frequently 
treated with numerous different antidepressants at the same time accompanied by phase 
prophylactics and other co-medicated drugs (e.g. neuroleptics, benzodiazepines or sleeping 
medication). Consequently, the classification of the cell lines into responders and non-responders 
might be error-prone which could lead to impaired results. For instance it is not possible to 
distinguish between single drug effects of patients polymedicated with various antidepressants: A 
patient - like donor of cell line “734” - treated with an SSRI and a NaSSA at the same time might be 
classified as responder whereby the main effect of recovery could be based on the treatment with 
the NaSSA and would not be reproducible in laboratory conditions using fluoxetine as indicator 
drug. A similar problem occurs in patients who were treated with a given antidepressant for a too 
short period of time to evaluate its effectiveness (e.g. less than three weeks). Although the patient 
would have been a responder to the given antidepressant, such switches probably were performed 
due to harming severe side effects which do not occur in cell cultures. Last but not least, further 
impairments of the results probably might be based on the fact that patients with different 
underlying diseases such as bipolar disorders, single episode major depressive disorders or 
recurrent major depressive disorders were recruited for the MARS study. Due to the heterogeneity 
of the MARS cohort the significance of our results might be reduced. In contrast, in STAR*D only 
patients with defined, nonpsychotic major depressive disorders were enrolled. A further limitation 
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is that the in vitro proliferation in LCLs was determined after incubation only with fluoxetine or 
citalopram which does not reflect the real treatment regimens. Taken together, the LCL cohort 
from the STAR*D study seems to be the more suitable one for our experimental approach because 
it is a defined cohort with uniform disease background which received antidepressant monotherapy 
so that the LCL donor’s response status is unambiguous.  
The individual proliferative effects observed here after long-term incubation with antidepressant 
drugs do not correlate with in vivo proliferative effects. No signs of cell proliferation stimulus on 
blood cells or bone marrow have ever been described for antidepressant drug therapy, but such ex 
vivo effects in the cell lines of depressed patients might contribute to the puzzle of explaining the 
high variability in antidepressant efficacy observed in clinical routine. However, one has to keep in 
mind that individual patient’s clinical efficacy could be different from those observed in LCLs and 
that the applicability of peripheral proliferation after long-term incubation with antidepressants as 
response biomarker seems limited. Aggravating, it is assumed that cellular proliferation as well as 
neurogenesis could be influenced by factors such as age 258, alcohol 259 and exercise 260. Our 
hypothesis is based on the assumption that antidepressants induce the proliferation of neuronal 
cells and therefore modulate the neural plasticity 261. Depressed patients show a volume reduction 
of depression-associated brain parts 16 that might be reversed by antidepressant-induced 
proliferation 262. The induction of neural stem cell proliferation is directly linked to an enhanced 
neuroplasticity which in turn leads to a normalization of the depressed brain function 263. This 
explanation helps understanding the delay in symptomatic improvement (from weeks up to several 
months) because cerebral remodeling processes are complex and time-consuming. Such direct 
proliferative effects of antidepressants and the role of neurotrophic proteins were analyzed by 
Chang and colleagues in human neuronal precursor cells 243. Other research groups reported 
proliferative effects in rodents, e.g. in hippocampal granule cells of adult mice 264, 265 and non-
human primates 266. Chen et al. studied the effect of chronic treatment with antidepressants on the 
number of hippocampal neurons in a genetic rat model of depression and concluded that 
antidepressants are able to induce neurogenesis and synaptogenesis 267. The molecular 
mechanisms underlying these neuro-proliferative effects and the remission of depression remain 
poorly understood, although neurotrophic growth factors - like BDNF - may play an important role 
during remission processes 268. Antidepressant effects are restricted to type 2 but not type 1 
neuronal progenitor cells accelerating the maturation of neurons 269, 270. Fluoxetine probably 
conveys the integration of newborn neurons into the functional networks like the dentate gyrus 
network or the hippocampal pyramidal cells of the HPA axis which leads to an improved cellular 
survival 130. All those findings along with our results support the neurotrophic hypothesis of 
antidepressant’s action which suggests an antidepressant-mediated reversal of impaired 
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hippocampal structure and activity. However, the relationship between SSRI-mediated in vitro 
proliferation and clinical efficacy remains in need of further investigation. Studying of molecular 
backgrounds and the identification of potential gene expression biomarkers associated with 
peripheral or CNS proliferation might be advantageous as well.  
 
 
4. Microarray-based Identification of Tentative Gene Expression Biomarkers  
 
Analysis of whole genome gene expression in LCLs becomes more and more important for the 
identification of tentative gene expression candidate biomarkers. In general microarray based gene 
expression has manifold advantages such as the simultaneous determination of expression levels of 
nearly all known human genes in one single experiment. Due to the hypothesis-free nature of 
genome-wide expression studies, results are unbiased and do not necessarily require pre-
experimental knowledge about underlying mechanisms or involved pathways. However, care is 
called when it comes to the interpretation of such data because false-positive events occur 
frequently and so, data need independent confirmation. 
Phenotyping the proliferative response of LCLs to fluoxetine (0.5 µg/ml; 21 d) followed by 
comparative microarray-based genome-wide gene expression profiling revealed 15 candidate genes 
out of 390 identified by pathway analyses. These genes can be assigned to either WNT signaling 
(e.g. WNT2B, FZD7, TCF7L2) or EGF signaling (e.g. BTC, EGFR, HBEGF) or to a group of 
pharmacokinetic genes (e.g. CYP3A43, SULT4A1, ABCB1, ABCG4) and will be further addressed in 
the following subsections (chapters 4.1 to 4.4). The gene CACNA2D3 - which probably possesses a 
role in long-term antidepressants action 174- cannot be classified into these groups. CACNA2D3 is a 
member of the voltage-dependent calcium channel complex which is expressed in the cerebral 
cortex amongst other non-neuronal tissues. It was reported that the gene expression of CACNA2D3 
in mice is increased after 28 days of treatment with the antidepressant amitriptyline 174. A calcium 
or calmodulin-dependent role of CACNA2D3 in regulation of transcription factors of cortical neuron 
formation was postulated but needs further investigation. However, Malmersjö et al. found calcium 
ion activity important for cellular proliferation in mouse neural progenitor cells 271. Another work 
reported calcium being involved in neurodevelopment, apoptosis or differentiation within a 
network of purinergic receptors 272. 
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4.1. Role of EGF Signaling in Depression 
In the microarray experiments, by far the strongest gene expression differences compared between 
responder derived cell lines relative to non-responder derived cell lines were obtained for 
betacellulin (BTC). BTC belongs to the epidermal growth factor (EGF) protein family and has been 
reported to stimulate neurogenesis 165 as well as neural stem cell proliferation and differentiation 
into glial- and neuronal like cell types 273. BTC is endogenously produced in the brain, especially by 
blood vessels and the choroid plexus and directly affects neuroblast differentiation and neuronal 
stem cell regeneration by activation of EGFR and ERBB4 (epidermal growth factor receptor 4). It is 
considered a potential therapeutic agent for treating neurodegenerative diseases 165. Further genes 
from the EGF pathway being involved in individual fluoxetine drug response were identified by our 
microarray approach such as ERBB3, MAPK9, PIK3R5, HBEGF and EGFR. ERBB3 is a receptor for EGF 
and an important element of the nervous system development 180. Furthermore it is required for 
the development and differentiation of the neural crest and glial cells 180, 274. HBEGF and EGFR are 
crucial for proliferation of astrocytes and neurogenesis as well as neural progenitor proliferation 
and migration, respectively 167, 177. HBEGF is an 87-amino acid glycoprotein and a growth factor 
targeting the EGFR amongst others. It is widely distributed in neuroglia and cerebral neurons where 
it is required to stimulate neurogenesis 275. A stimulation of EGFR on the other hand - through for 
example EGF, TGF alpha, HBEGF, BTC and many more 276 - activates a signaling cascade ending in 
increased cell proliferation, adhesion and survival. A recent study presented a role of EGFR in 
neuronal protection from stress 277 and mutations within the EGFR gene have been associated with 
a decreased frequency of depressions and a lower depression severity in oncologic patients 278. 
MAPK9 is an enzyme involved in a wide variety of cellular processes like proliferation and 
transcription regulation. This kinase inhibits the degradation of cell cycle protein p53 and therefore, 
regulates apoptosis - mainly in dopaminergic brain areas 178. Mitogen activated protein kinases are 
generally required for neuronal plasticity, survival and differentiation. Additionally, it was recently 
shown that MAPK9 was downregulated in dermal cells derived from patients suffering from bipolar 
depressive disorders 279 suggesting a role in psychiatric dysfunction. PIK3R5 is a regulatory subunit 
for PI3Ks (phosphatidylinositide 3-kinases) that play important roles in cell growth and 
proliferation. Furthermore, PIK3R5 is a circadian gene involved in sleep-wake cycles and therefore, 
in insomnia 169 - one of the main side symptoms of depressive disorders. An impaired gene 
expression of PIK3R5 is a risk factor for suicidal behavior 170, 171. 
 
4.2. Role of WNT Signaling in Depression 
The transcription factor TCF7L2 and the receptor FZD7 belong to the canonical WNT signaling 
pathway which plays an important role for regulation of stem cell pluripotency and cell 
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differentiation by integrating signals from other pathways and their associated signal molecules 
such as fibroblast growth factor and bone morphogenic protein 280, 281. Both growth factors are 
involved in depression pathogenesis 282, 283 and - together with other downstream growth factors 
like BDNF, VEGF (vascular endothelial growth factor) and other signaling pathways - in the 
maintenance of adult hippocampal neurogenesis 284, 285. Further, WNT signaling regulates 
neurogenesis, synaptic plasticity and dendritic arborization 286. WNT2B is a highly conserved signal 
peptide and a ligand for members of the frizzled transmembrane receptor family. FZD7 - being a 
receptor for WNT proteins in the brain - belongs to this family of G protein-coupled receptors 173. 
WNT2B is involved in regulation of cell growth and differentiation 166. WNT glycoproteins usually 
are liberated from hippocampal astrocytes and show short-ranged action. They take effects 
through gene expression activation of NeuroD (neurogenic helix-loop-helix protein) and Dcx 
(neuronal migration protein doublecortin) 287, 288, a transcription factor involved in CNS 
development and a microtubule-associated protein almost exclusively expressed in actively dividing 
neuronal precursor cells, respectively 289, 290. An activated Wnt signaling pathway supports the 
differentiation of specific glial neuronal precursors 291, controls stem cell pluripotency and tissue 
regeneration 292 and regulates the expansion of CNS progenitor cells 293. Furthermore, WNT 
proteins are involved in immunological processes of microglia 294 - macrophage-like cells of the 
brain that are required for CNS homeostatic functions 295. Neurotoxic agents reduce WNT 
expression in developmental hippocampal neurons 296. Furthermore, Wnt signaling regulates adult 
hippocampal neurogenesis 297 and the expansion of CNS progenitor cells 298. Moreover, it is 
important for synaptic function as well as for the formation of hippocampal spines 299, 300. A 
malfunction of Wnt signaling in the hippocampus by targeted knockdown is associated with 
decreased neurogenesis, increased depression-like behavior and various neuropsychiatric disorders 
286, 301. It has been shown that Wnt signaling is responsive to various antidepressant drugs 302 while 
mice with constitutively activated Wnt signaling become irresponsive to antidepressant treatments 
303. Furthermore, a role of Wnt signaling via the fast acting antidepressant ketamine has been 
proposed 304.  
 
 
4.3. Role of Drug Metabolizing Enzymes in Depression 
Although the sequence of SULT4A1 is highly conserved between mammalians suggesting an 
important function 305, 306, little is known so far about the brain specific phase II metabolizing 
enzyme SULT4A1. It may be involved in the metabolism of antidepressant drugs and neuroactive 
substances. However, since expression of SULT4A1 was low in LCLs and only detectable in 21 out of 
100 cell lines, our results should be seen with caution and warrants further analysis of SULT4A1 
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expression in brain. SULT4A1 seems to conjugate drugs and neurotransmitters specifically within 
the brain 172, 307. An association of polymorphisms within the SULT4A1 gene and the susceptibility to 
neurological disorders like schizophrenia has been described 308. Its higher expression in females 309 
may be associated with the higher prevalence of depression in women. Interestingly, the gene 
expression of SULT4A1 is regulated by CREB (cAMP response element-binding protein) 310, a 
transcription factor that plays a major role in neurogenesis and synaptic plasticity 311. Furthermore, 
CREB is involved in pathological and pharmacological actions of depressions, since decreased levels 
of CREB in the prefrontal cortex of depressed patients were shown 312. Effects of SSRIs on CREB 
concentrations through the course of treatment were reported with lowered CREB levels in 
responders than in non-responders 313. 
The monooxygenase CYP3A43 shares a testosterone hydroxylase activity and seems to be involved 
in lipid and steroid synthesis as well as in antipsychotic drug metabolism 168, 314. It is a homologue to 
other drug metabolizing CYP enzymes, but it shows no proven cerebral expression and probably 
does not significantly contribute to the metabolism of xenobiotics or drugs 315. However, since 
CYP3A43 is involved in hormone metabolism, one might speculate about a role of CYP3A43 within 
the context of the hormone-based hypothesis of the pathogenesis of depression (see chapter 2.1). 
Levels of steroidal hormones such as cortisol or estrogen have been associated with a higher risk of 
depressions and with more effective antidepressant therapies 20, 21. 
 
4.4. Role of Drug Transporters in Depression 
ABCG4 belongs to the ATP binding cassette (ABC) superfamily and is involved in the regulation of 
cholesterol and lipid homeostasis in neurons and astrocytes 175, 176. It plays a role in fear processing 
in mice 316 and was suggested to be implicated in the development of neurodegenerative disorders 
such as the Alzheimer's disease 317. A known direct relation between ABCG4 activity and depressive 
disorders is missing. However, abnormality in lipid homeostasis may lead to increased production 
of reactive oxygen species which in turn, is connected to pathophysiological processes in 
depressions 318, 319.  
The plasma membrane transporter ABCB1 possesses a key role in cellular detoxification and 
transmembrane transport across the BBB back into the circulatory system. Furthermore, it 
contributes to the biliary and renal elimination of drugs 320, 321 and represents a major component 
of the intestinal barrier 322. ABCB1 is an efflux pump with a broad allocrite spectrum including a 
variety of drugs (e.g. antidepressants, glucocorticoids), xenobiotics as well as neurotoxic agents 179 
and thus, ABCB1 holds neuroprotective effects eventually resulting in an increased response to 
antidepressant mediated induction of neural proliferation and plasticity. Peripheral glucocorticoids 
are stress response factors in the HPA axis, normally have toxic effects on neurons and are 
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suspected to be causative for depressions 323. Furthermore, a dysfunction of glucocorticoid 
receptors modifies the functional integration of neurons in the hippocampus and therefore, leads 
to an impaired synaptic connectivity and fear-motivated behavior in animal experiments 324. Studies 
using ABCB1 knock-out mice or ATPase assays in human ABCB1 membranes have shown that most 
antidepressants such as amitriptyline, doxepin, paroxetine or citalopram are strong allocrites of this 
transporter 185, 325-328 and overexpression of ABCB1, i.e. increased removal of antidepressants from 
the brain, might explain non-responsiveness to various antidepressant drugs 329. Hence, numerous 
variations in the ABCB1 gene were reported influencing the plasma levels of antidepressants as well 
as the treatment efficacy 330-336. Fluoxetine, one of the antidepressants we employed for in vitro LCL 
phenotyping, is only a weak allocrite of ABCB1 337, 338. One may speculate that the absence of a 
correlation between fluoxetine induced ABCB1 expression and clinical response of the MARS cohort 
could reflect the low ABCB1 allocrite properties of this antidepressant drug. Carriers of defined 
haplotypes within the ABCB1 gene show decreased risk of developing depressions 339 and 
polymorphisms of the ABCB1 gene are thought to predict adverse antidepressant drug effects 340. 
Furthermore, other polymorphisms might predict the individual response and dose adjustment to 
the antidepressant escitalopram and are associated with depression severity 335, 341. All these 
findings point to a significant involvement of ABCB1 in depression. 
 
 
5. Validation of Tentative Gene Expression Biomarkers 
 
Five genes (WNT2B, TCF7L2, FZD7, SULT4A1 and ABCB1) were differently expressed in an edge-
group approach, i.e. in cell lines with the highest increase vs. highest decrease in cell proliferation 
following 21 d fluoxetine incubation. Analyzing extreme phenotypes is an emerging method in 
pharmacogenomical research since it time- and cost-effectively allows the discrimination of genes 
involved in processes of interest. The observed effect size is increased compared with results from 
cell lines with average phenotypes and consequently - as done over the course of this work - the 
findings need to be verified in the total population 342. Initially, this approach was developed in the 
field of oncology leading to the identification of various biomarkers to predict effects of anticancer 
drugs like cisplatin 343, cytosine arabinoside 344 or etoposide 345 but is now of growing interest in 
neuropsychiatric indications. For example, Morag et al. identified potential genetic biomarkers in 
edge-groups from paroxetine sensitivity phenotyping experiments 117. 
Further data analysis containing results from all available cell lines showed a correlation between 
LCL donor’s clinical responses with the LCL basal gene expression of SULT4A1. Furthermore, the 
gene expression fold changes of WNT2B by fluoxetine incubation correlated with clinical remission. 
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None of the remaining genes TCF7L2, FZD7 and ABCB1 showed significant correlation with clinical 
parameters of LCL donors from the MARS study. In contrast, associations between LCL donor’s 
clinical response and LCL basal gene expression of WNT2B and ABCB1 but not for FZD7, TCF7L2 or 
SULT4A1 could be found in the cohort derived from patients participating in the STAR*D study. 
Furthermore, the fold changes by fluoxetine and citalopram of WNT2B, FZD7 and ABCB1 showed 
correlations with LCL donor’s clinical response and remission status. In general remission - defined 
as the virtual absence of depressive symptoms - is assumed to be the more robust outcome 
parameter compared to response which is characterized by a 50% reduction of symptomatology 346. 
This, together with the fact that patients showing remission demonstrated decreased relapse and 
suicide 347, is why remission predicting biomarkers should be given the virtue. Since the results were 
more or less reproducible in the different cohorts (MARS and STAR*D), the genes can be assigned 
as putative gene expression biomarkers acting as potential temporal mediators (variables whose 
initial early change during treatment could be associated with future treatment outcome) or 
baseline gene expression predictors (variables associated with treatment efficacy before therapy 
start) that eventually advance the personalized treatment approach in depressions in the future. 
 
 
6. Interferon beta, Sickness Behavior and Depression 
 
In 17 healthy participants (7 males and 10 females with a mean age of 26.5±4.9 years), 
questionnaire based evaluations of interferon-induced mood changes (STAI and HDRS) were carried 
out. The STAI intends to measure general propensities to be anxious and current symptoms of 
anxiety through simple self-report algorithms. Since anxiety is one of the main symptoms of 
depressive disorders a correlation of STAI results with depressive states has been described 
frequently 348. Furthermore, high test-retest reliability coefficients as well as the ability to detect 
individual changes were reported in the literature 349. The HDRS was actually developed to provide 
indications of depressions and to evaluate recovery, but here it was used to assess interferon-
induced changes in behavior and mood. It is one of the most used depression rating scales 
characterized by high internal consistency, inter-rater reliability and test-retest reliability 350. The 
observations from behavioral testing showed significant increased depression scores (HDRS) but no 
significant changes in anxiety levels (STAI). Maybe a possible individual interferon-induced anxiety 
interferes with increased anxiety level of fearful participants during their first MRI scan session 
(questionnaires were conducted immediately before the MRI measurement) leading to impaired 
results. When analyzing the single items of the HDRS, depressive main symptoms (e.g. depressed 
mood or anhedonia) were barely detected, but other depression-related symptoms such as feelings 
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of fatigue or weakness, concentration problems, insomnia, etc. were frequently recorded. These 
results suggest an induction of sickness behavior by interferon beta but not of depression itself 
which is an interesting new aspect of the current pharmacological research. For that reason the 
following part summarizes the knowledge about the connection between immune system 
activation and the development of depressions considering molecular backgrounds, brain 
functioning in the key sites, treatment effects and the possible role in personalized medicine.  
In the early 1990s a role for cytokines in depression was proposed as a part of the macrophage 
theory of depressions 351. A few years later it was described that pro-inflammatory cytokines are 
able to cause some clinical aspects of depressive disorders such as the disturbance of the serotonin 
metabolism, the hyperactivity of the HPA axis and most of the neuro-vegetative symptoms (e.g. 
appetite disturbance, fatigue, concentration problems, etc.) 352. Depressions have been associated 
with a pathologic activation of the immune system characterized by increased levels of T cells and 
acute phase proteins 353, 354. In general symptoms of sickness behavior and depression are tightly 
connected and a common pathophysiology is suggested 355. For instance both phenomena are 
caused by or led to a decreased reactivity to reward, a withdrawal from social or physical 
environment as well as pain and malaise 25. The detailed mechanisms behind these behavioral 
changes remain unclear. The amygdala seems to be a neural key region that is involved in sickness 
induced social withdrawal in animals 356. In accordance to this, social avoidance tendencies are 
associated with elevated amygdala activities to negative social cues in humans 357-359. In animal 
models induced depression-like behavior was linked to an exaggerated inflammatory response in 
the brain with aged mice being more sensitive 360. Consistent with this the onset of depression was 
shown to be preceded by elevated biomarkers of inflammation in a cohort of elderly participants 
361. Furthermore, the symptoms of both sickness behavior and depression can be successfully 
treated by antidepressive drugs. Patients with exaggerated inflammatory blood markers are more 
likely to show treatment resistance to antidepressants 362. However, in this context depressive 
disorders seem to be caused by a dysfunction in neuronal circuits of cytokine-induced responses 
since an increased vulnerability to depressions was reported in persons with an overactive CRH 
system 363. In such vulnerable individuals, (chronic) inflammatory processes like systemic infections 
or autoimmune diseases are able to influence the brain functions and therefore, to guide from 
sickness behavior to depression 364. Several mechanisms to explain these effects of peripheral 
cytokines on the CNS are proposed, e.g. a role of post-infection activation of primary afferent 
neural tracts like the vagal nerve is discussed 365, 366. Furthermore, peripherally circulating cytokines 
are able to increase the production of centrally-acting pro-inflammatory cytokines by activation of 
macrophage-like cells from the circumventricular organ - a specialized organ of the brain ventricular 
system that is an integral part of the neuroendocrine function 367 - in a toll-like receptor mediated 
Chapter V - Discussion 
83 
manner as part of the humoral pathway response. Additionally, blood cytokines are able to enter 
the brain directly either by volume diffusion 368 or by active transport mediated by cytokine 
transporters of the BBB 369, 370. Cytokines are able to counteract and prevent antidepressant actions 
including effects on neurotransmitter function and synaptic plasticity 63. Cytokines can influence 
neurotransmitter synthesis, release and reuptake by various mechanisms. A cytokine-induced 
activation of the indoleamine-2,3-dioxygenase (IDO) that metabolizes tryptophan - the serotonin 
precursor - leads to a reduced availability of serotonin in the brain 25 and to the development of 
depression-like behavior in animal experiments 371, 372. The expression of neurotransmitter reuptake 
transporters is increased by inflammatory cytokines in a mitogen-activated protein kinase (MAPK) 
dependent manner 373-375. Interferons are glycosylated hormone proteins with immunomodulatory 
effects that probably act via receptor-associated tyrosine kinases followed by an activation of the 
JAK/STAT cascade resulting in an activation of immune cells (e.g. monocytes, leucocytes) as well as 
an increased expression of human leukocyte antigen molecules and other mediators of immune 
reactions like cytokines. This might be a possible mechanisms of action with respect to the 
mentioned immunologic effects. Pro-inflammatory cytokines such as interleukins or TNFs usually 
are responsible for acute-phase reactions (e.g. after an infection) and they are peripherally 
produced by accessory immune cells like dendritic cells or macrophages. Cytokine-induced sickness 
behavior is caused by pro-inflammatory events in the brain mediated mainly by the interleukins IL-
1a, IL-1b, IL-6, IFN-b and TNF-alpha. A stimulation of the sympathetic nervous system by stress is 
also able to activate inflammatory signaling pathways 376. Consequently, the option to treat 
depressions with anti-inflammatory drugs was hypothesized and some evidence for a positive 
therapeutic effect of TNF or COX inhibitors was identified recently, but further investigations 
concerning the pathophysiology of inflammation and depression-like behavior are necessary to 
advance this approach 377-381.The identification of subgroups of depressed patients being responsive 
to immunotherapies would be beneficial in the view of treatment personalization. Additionally, 
lower levels of TNF-alpha have been linked to response to the antidepressant amitriptyline 362. 
There is growing evidence that inflammatory processes might have a greater influence on the 
pathogenesis of depressions than the traditional psychosocial factors (e.g. negative life events, 
chronic stress or lack of social contacts). In animal experiments, an activation of the immune 
system led to a decrease of the preference for drinking and food intake 356 and the effect size was 
reduced after the pre-treatment with antidepressants 382. A higher sensitivity towards interleukin-
induced negative mood was reported in a genetic model of depression 383 and cytokines were 
shown to be able to increase the serotonin turnover in the brain 373, 384. Furthermore, both 
physiological and psychological risk factors play an important role in the vulnerability to 
immunotherapy-induced depression. For example an enhanced response of the HPA axis 385, 386 and 
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elevated depression scores before begin of the therapy have been associated with depression 
severity 109. The HPA axis can be activated by neuropeptides like vasopressin or corticotropin-
releasing factors which are known to account for depressive symptoms 387, 388.  
 
 
7. Functional Neuroimaging 
 
Functional neuroimaging is an important instrument to assess neurobiological correlates of drug 
effects in the brain due to its non-invasivity and wide applicability in the clinical setting. Several MRI 
studies have been successful in identifying the changes in specific brain structures induced by 
medication 389, 390. As the core symptoms of depressions are reflected by an impaired reward 
processing and emotion regulation 30, we focused on these neural circuits using particular fMRI 
paradigms (foraging and faces, respectively). One important concern was to evaluate the 
applicability to depict cytokine-induced sickness behavior or depressions via fMRI. However, a few 
limitation of our fMRI study have to be mentioned. First, no control group was enrolled so far (but 
is planned for the future) in this study leading to the fact that effects of repeated measurements 
remain unconsidered. Since the study was not double-blinded and randomized, the implementation 
of a well-matched control group is absolutely essential. The sample size of this study is small and 
therefore the results possess only low statistical power. Additionally, since the relationship 
between clinical characteristics and brain activity is very complex and not well understood so far, 
the transferability of our result’s use remains unknown. But the measurement of dysfunctions in 
above described neural circuits detected by fMRI will provide further information regarding this 
issue and may be helpful in individual guidance of diagnostics of depression and antidepressant 
treatment selection in the future. 
 
7.1. Responses to Emotional Faces after Interferon Administration 
The faces paradigm was assigned to evaluate reactivity to emotional stimuli like anger, sadness or 
disgust in a passive exposure paradigm whereby the region of interest was the amygdala. No 
significant differences in amygdala activation before and after interferon administration were 
detectable which might be based on different reasons (such as the unsuitability of the faces 
paradigm to depict processes of drug-induced depressions, i.e. other regions - that are not covered 
by the faces paradigm - might be more relevant to the pathogenesis of drug-induced depressions 
under consideration of emotional processes or the fact that the duration of drug intake was not 
sufficient to fully develop activation differences in the amygdala). However, the faces paradigm is a 
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robust standard method to measure amygdala activation 159, since the amygdala activation can be 
measured (also when the presentation of the faces is subliminal) and drug effects are depictable 391. 
Nevertheless, the latest literature regarding the phenomenon of facial emotion deficits in 
depressive disorders will be discussed in the following section since it is widely accepted that such 
processes play a key role in depression and there is huge evidence for abnormal emotion 
recognition in this disorder.  
Impaired facial emotion recognition is symptomatic for many psychological diseases including 
schizophrenia, alcoholism, autism, anxiety, bipolar disorder and depression 392-397. Since emotional 
perception is crucial to social interaction which is one important factor of individual well-being in 
depressions 398, 399, the role of emotion recognition in depression is of high relevance (reviewed by 
Bourke et al. 400). Emotional processes are usually regulated by the interaction of top-down control 
processes in the prefrontal cortex and bottom-up processes triggered by emotional stimuli 133. 
However, here we did not find any significant changes in amygdala activation after the short-term 
treatment with interferon beta indicating no specific role of the amygdala in the rapid action of 
interferon-induced sickness behavior or depression. In contrast, Whalen et al. reported a 
modulated reactivity in the limbic system after interferon beta treatment in depressive patients 401. 
Many studies have demonstrated a relationship between local inflammation, regional brain 
activation and emotional processing 402. Additionally, using fMRI techniques it was convincingly 
shown in numerous studies that the reactivity of the limbic and paralimbic systems to emotional 
stimuli (e.g. sad faces) is impaired in depressive patients. Recent meta-analyses identified moderate 
emotion recognition deficits in depressed patients 403, 404. Another meta-analysis reported uniquely 
preserved recognition of sadness while the recognition of the other basic emotions (anger, disgust, 
fear, happiness, surprise) is impaired 405. Frodl et al. reported an increased activity in the limbic 
system to emotional stimuli in depressed patients compared to healthy controls 406. Such 
abnormalities are associated with constructs in the negative valence system like acute and chronic 
anxiety or fear. Pharmacological treatments have been shown to normalize pathologically elevated 
activity in these circuits 407-412. Antidepressant drugs were shown to alter the recognition of 
emotion 413, 414 and to reduce the neural responses to negative facial expressions 415. Several genetic 
variants within neural genes were associated with impaired emotion processing and with poor 
response to antidepressants. For example a variant of neuropeptide Y (rs16147) - a 
neurotransmitter of the autonomic nervous system involved in stress and anxiety processing - has 
been linked to an exaggerated amygdala reactivity to emotional faces and to a decreased treatment 
outcome in patients with anxious depression 416. Another study reported a connection between 
reduced response of the striatum and the thalamus to happy faces, a decreased response to 
antidepressant drugs and a genetic variant of the cannabinoid receptor type 1 (rs1049353) - a 
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receptor of the endogenous cannabinoid system that is required for the development of the brain 
and for the response to stress and anxiety 417. Furthermore, an aberrant activity of the amygdala to 
sad facial emotions is specific to depressive states and therefore appointed as a potential 
biomarker for negative affective bias during depressive episodes 410. Consequently, the limbic 
reactivity to emotional faces measured by MRI techniques could be helpful in the future for early 
medication screening or to predict the individual treatment outcome in depression 410, 418. 
 
7.2. Responses to Monetary Reward after Interferon Administration 
The foraging paradigm was employed to probe the impact of interferon therapy on the sensitivity 
to reward cues. We measured a decreased activity of the dopaminergic ventral striatum following 
the treatment with interferon beta in this money-rewarding paradigm. Changes in dopamine 
function are correlated with behavioral changes such as depression or sickness symptoms. The 
dopamine-modulated cortical cortex including the ventral striatum possesses a key role in reward 
processing regulated by the orbitofrontal cortex 419, 420. Other brain structures like anterior 
cingulate cortices or the ventromedial prefrontal cortex were described being involved in reward 
expectancy or processing 421-423. Dysfunctional reward circuitries have frequently been associated 
with depression. For example, depressed patients showed increased activities of the anterior 
cingulate cortex to previously rewarding stimuli (but less activity of the ventral striatum), to 
expectancy of monetary reward or to reward learning 424-426. Other studies reported reduced 
ventral striatal activities during reward learning and to rewarding stimuli in depressed patients 
relative to healthy controls 425, 427-430. Dopamine and various pharmacological treatments (e.g. 
levodopa, duloxetine or dextroamphetamine) were shown to alter these processes by modulation 
of the activity of the ventral striatum 431-433. Furthermore, a normalization of functional 
abnormalities within the reward system was observed after psychotherapy 434. Interferons are 
known to target CNS structures like the basal ganglia of the ventral striatum amongst others which 
has been shown by positron emission tomography imaging or fMRI 364, 435. For example a decreased 
activation in the ventral striatal region was shown in a reward paradigm of patients suffering from 
hepatitis C being treated with interferon 436. Another study demonstrated that inflammation alters 
reward-related neural correlates of anhedonia - a key symptom of depression - to monetary reward 
cues by a reduction of the ventral striatum activity 437. Abnormalities in reward neural circuits are 
responsible for the depressive symptoms of apathy and anhedonia that in turn might be connected 
to constructs in the positive valence system 427, 438.  
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8. Outlook / Future Perspectives 
  
Since depressions already belong to the most prevalent mental illnesses affecting over 350 million 
people worldwide and the prediction that depressive disorders will account for the largest part of 
the economic burden within the next twenty years 9, the improvement of the individual 
antidepressant therapy of this serious mental illness will become inevitable. The total number of 
affected people will raise even more dramatically in the future because the world population is 
rapidly growing, diagnostical tools will find their way in the improving medical systems of today’s 
third world countries (where depression might be underdiagnosed nowadays 439) and 
environmental conditions as contributory causes (e.g. chronic stress and fear, progressing 
urbanization accompanied by increasing social isolation etc.) will worsen. Additionally, more 
significance will be given to heritability factors of depressions. The introduction of gene 
therapeutical approaches into clinical practice might be a solution. Another interesting approach to 
reduce depression rates could be vaccination 440, normalizing the imbalance between pro- and anti-
inflammatory cytokines frequently reported in depressive disorders (compare with chapter 2.1, 
immunological hypothesis). However, gene therapy and vaccination are experimental approaches 
that might become relevant in the distant future. Since genetic biomarkers are more objective 
parameters compared to behavioral scales they will be more efficacious in personalized therapies in 
the field of depressive disorders 441. For that reason treatment individualization using genetic 
biomarkers remains in the focus of research in the short to medium term. This turned out being a 
challenging aim due to high complexity and individuality of depressions and consequently, 
identifying single universal parameters to predict individual treatment responses seems impossible. 
Hence, biomarker signatures of validated parameters on DNA, RNA and protein level will be 
necessary and be the future of personalized medicine in depressive disorders. The development of 
fast and easy to use methods (like the cobas® EGFR mutation test kit used for therapy 
individualization of patients suffering from non-small cell lung cancer 3) covering such biomarker 
signatures would be the best solution to further advance the field. The candidate genes reported 
here could be a part of such biomarker signatures. They should be further examined for their 
molecular validity, pharmacogenetical variability and their role in remission from depression. The 
molecular validity of these genes could be verified by detection of their gene products on protein 
level for instance using immunological methods like ELISAs (enzyme linked immunosorbent assay) 
or Western Blots. The pharmacogenetical validity may be proven by knockdown or miRNA silencing 
experiments of the mentioned genes in LCLs, animal models for depression or human neuronal cell 
lines (e.g. neuroblastoma cell line SH-SY5Y or cortical neuron cell line HCN-2) with subsequent 
determination of effects on the SSRI-mediated proliferation induction. Another interesting 
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approach is the generation of neuronal cells from LCLs derived from depressive patients by 
reprogramming technology using retroviral or virus free (transcription factors and small molecules) 
methods 442, 443. Additionally, the role of the candidate genes in remission from depression could be 
evaluated using longitudinal blood samples from major depression patients participating in 
prospective, controlled clinical trials. After confirmation of their predictive potential the gene 
expression levels of ABCB1, FZD7, SULT4A1 and WNT2B might support the guidance of individual 
AD therapy choices in the future and therefore, such genetic biomarkers will further lead to the 
eradication of trial and error prescription.  
 
Away from this, another interesting and promising approach to pave the way for the entry of the 
individualized medicine into the important indication of depressive disorders is the usage of 
neuroimaging techniques. Here, we found evidence for individual variability in drug-induced 
depression as well as an impaired reward system functionality being highly involved in interferon-
beta induced sickness behavior. Transferring this knowledge to depression itself one might 
speculate about a more important role of a well-working reward system in depressions than 
previously thought. However, the short-term aim is to verify and validate the obtained results that 
so far lack evidence of no or insignificant impact of repeated measurements on individual brain 
activities targeted by our fMRI paradigms. Since the test-retest-reliability of fMRI paradigms is 
frequently underrated 444, 445, identical measurements in unmedicated, matched healthy volunteers 
should and will be added as a control cohort. Here, we only described two different paradigms 
targeting anxiety and reward behavior, but the actual MRI measurement battery consisted of more 
sequences such as other functional MRI paradigms targeting further depression-associated 
conditions (e.g. anhedonia, negative cognition) as well as perfusion and diffusion measurements. 
Since perfusion imaging is a hypotheses free approach to measure brain activity, it could shed light 
on further, unknown brain regions involved in interferon beta action and the development of 
depression-like behavior or depressions itself. Diffusion imaging is an innovative MRI-based 
technique that measures the degree and directionality of the diffusion of water molecules in the 
brain and that can be used to detect changes of the axonal organization (e.g. axon density, axon 
diameter, myelination) and neuroplasticity 446. These approaches will surely deliver further 
interesting results improving our understanding of individual effects of interferon beta. One - so far 
unfinished - aspect of this study was to correlate MRI data with transcriptomic data. The 
connection of these “big data” may be beneficial to accelerate psychiatric biomarker and treatment 
development and to improve our understanding of the molecular neurochemical and 
neurogenetical mechanisms behind drug-induced depressions and depressions in general 122, 447. 
This approach might help to identify genetic vulnerability markers of psychiatric diseases as well as 
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the effects of gene expression differences to structure and function of the brain. Furthermore, the 
prediction of affective interferon side effects could be helpful for the therapy guidance of MS 
patients and to reduce their suffering 88. It was frequently shown that individual variability in brain 
functions can be depicted by MRI measurements 448. In the future functional connectivity profiles 
may act as intrinsic fingerprints 449 which probably allow the accurate distinction of depressed from 
healthy subjects or from subjects with other neurological diseases (e.g. epilepsy or schizophrenia) 
within large cohorts. Another application could be the prediction of non-response or response to a 
given antidepressant drug. However, the identification of such fingerprints being clearly associated 
with depression will be one challenge of the future. In contrast, inflammatory biomarkers that 
reflect activation of relatively unique and specific pathophysiologic pathways might be helpful in 
the individual therapy because here we have shown that interferons are able to decrease the 
reactivity of the reward system which is probably based on inflammatory processes.   
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Chapter VI - Summary 
 
The understanding of the individual variability of depressive disorders is in urgent need of 
improvement which could be accelerated by identification of biomarkers for the diagnosis and 
treatment individualization of depressions. Here, we focused on the identification of potential 
biomarkers by application of cell based and neuroimaging based approaches to further advance the 
field of personalized medicine of depressive disorders. 
The therapy effectiveness of antidepressant treatments requires improvement due to low response 
rates, a delay in clinical improvement and the lack of predictive biomarkers. Since depressions seem 
to be associated with decreased hippocampal volumes and antidepressant treatments are able to 
stimulate neurogenesis, individual susceptibility to antidepressant induced proliferation may act as 
a surrogate marker for the prediction of expected individual responses to antidepressant drugs. 
Here, we measured proliferative effects by SSRI antidepressant drugs in human LCLs derived from 
depressed patients participating in large depression trials (MARS and STAR*D) with monitored 
response progresses. LCLs are emerging models in neuropsychiatric biomarker research as they are 
widely available from different populations, represent individual donor’s properties and show 
similar gene expression profiles with neuronal cells. Increased proliferation rates were detectable 
after three weeks of in-vitro treatment at the earliest with therapeutical concentrations of 
fluoxetine or citalopram which is in accordance with the observed delay in clinical improvement 
from several weeks up to a few months. A high variability in individual peripheral proliferation was 
reported in cohorts from both studies, but significant overall proliferative effects by 
antidepressants were restricted to the STAR*D cohort. Responder-derived LCLs showed 
significantly increased proliferation rates relative to non-responder derived cell lines and QIDS 
reduction was highly correlated with relative individual proliferation rates supporting the 
neurotrophic hypothesis of individual antidepressant efficacy. Because the underlying molecular 
backgrounds of individual antidepressant response remain poorly understand, we conducted 
transcriptome analyses in order to identify potential gene expression biomarkers associated with 
fluoxetine-induced peripheral or CNS proliferation. Comparative data analysis between non-
responder and responder derived LCLs revealed 15 candidate biomarker genes being involved in 
either EGF signaling or WNT signaling or metabolism and transmembrane transport. Significant 
correlations between clinical parameters of LCL donors and gene expression levels have been 
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detected for ABCB1, FZD7, SULT4A1 and WNT2B. The ABC transporter ABCB1 - better known as Pgp 
or MRP1 - holds a key role in neuroprotection by exporting neurotoxic agents back into the 
circulatory system, whereas the brain specific phase II metabolizing enzyme SULT4A1 is probably 
involved in the metabolism of neuroactive substances and antidepressant drugs. Both FZD7 and 
WNT2B are important parts of the canonical WNT pathway that is crucial for the regulation of stem 
cell differentiation, neurogenesis and synaptic plasticity. With this we identified potential baseline 
gene expression predictors and temporal mediators that might support the guidance of individual 
therapy regimes in depressed patients and help to advance the personalized treatment approach in 
depressions in the future. 
 
Another approach that might support the advancement of this field is the usage of neuroimaging 
techniques such as fMRI which has the potential to support the differential diagnosis of depression 
or to predict non-response or response to antidepressants. Here, we performed a clinical study to 
explore the individual variability of drug-induced depressions. Participants of this study were 
screened for depressive symptoms by psychometric testing and for changes in activation patterns 
of depression-related brain regions using fMRI techniques in order to find evidence for the 
depression inducing side-effects of interferon beta.  
Psychometric testing included anxiety and depression questionnaires and showed individual 
responses to the interferon administration. Highly significant changes where reported only for the 
HDRS and the particular single item analysis led us to the conclusion that interferon treatment 
initiates inflammatory processes resulting in sickness-behavior but not in depression in the strict 
sense. Indeed, pathologic immune system activations and depressive-like behavior were frequently 
shown to be tightly connected and it is proposed that inflammatory processes might have a greater 
influence on the pathogenesis of depressions than the traditional psychosocial factors. Sickness-
behavior and depressions share common pathophysiologic mechanism and are responsive to 
antidepressive therapies. During the fMRI sessions, conducted before and after interferon beta 
administration, the participants were instructed to complete two tasks that target specific 
depression-related brain functions (emotion processing and reward system). Although the role of 
emotion recognition in depression is usually of high relevance, we did not find any significant 
changes in amygdala activation after the short-term treatment with interferon using a passive 
exposure paradigm to emotional faces. In contrast, we measured a significantly decreased activity 
of the ventral striatum following the treatment with interferon beta in a money-rewarding 
paradigm. After exposure to interferon beta in healthy volunteers, we detected changes in the 
reward system functionality consistent with the existence of an anhedonia-like syndrome, while 
reactivity to salient negative stimuli was absent. This pattern was in accordance with the lack of 
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change in anxiety scores in behavioral testing (usually present in depression), outlining a specific 
syndrome accompanying the depression-inducing action or sickness behavior of interferon. After 
long-term therapy, this sickness behavior might turn into serious depression through cytokine 
actions in the brain because chronic inflammation seems to be a strong risk factor for the 
occurrence of depressive episodes. Based on our data one might speculate that interferon beta 
mainly affects dopaminergic circuits of reward and not serotonergic circuits of emotion recognition. 
We therefore propose that the depression-inducing effects of interferon beta after long-term 
therapy are at least partly based on an impaired reward system functionality.  
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Abbreviations 
 
ABC ATP binding cassette 
ABCB1 ABC transporter subfamily B member 1 
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Appendix 
Lab Equipment 
Centrifuge 5415 D  Eppendorf, Germany 
Centrifuge 5415 R  Eppendorf, Germany 
Centrifuge 5702  Eppendorf, Germany 
Centrifuge 5804  Eppendorf, Germany 
Centrifuge 5810 R Eppendorf, Germany 
CO2 incubator  Binder, Germany 
FACSCalibur BD Biosciences, Germany 
Hybridization oven  Agilent Technologies, USA 
Inverse light microscope Axiovert 40C  Zeiss, Germany 
Laminar flow cabinet HERAsafe  Heraeus, Germany 
LightCycler® 480  Roche, Germany 
LightCycler® 480 II Roche, Germany 
Mastercycler gradient  Eppendorf, Germany 
Micropipettes  Eppendorf, Germany 
MixMate plate stirrer  Eppendorf, Germany 
MS3 Basic shaker IKA®, Germany 
Multipette® plus  Eppendorf, Germany 
NanoDrop 1000 spectrophotometer  Thermo Scientific 
Pipetboy  Integra, Switzerland 
Safire² microplate reader Tecan, Switzerland 
SureScan Microarray Scanner Agilent Technologies, USA 
TC20™ cell counter  BIO RAD, USA 
Water bath  GFL, Germany 
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Lab disposables / Labware 
Pipette tips, sterile with filter  Sarstedt, Germany 
Flat-bottom 96-well sterile plates  Becton Dickinson, USA 
Cell culture flasks T25, T75  Sarstedt, Germany 
Combitips plus  Eppendorf, Germany 
Cryo Tube vials  Nunc, Denmark 
DMSO safe Acrodisc syringe filters  PALL, Germany 
FACS tubes VWR, Germany 
Glass vials, brown  Agilent Technologies, Germany 
LightCycler 480 multiwell plate 96, white  Roche, Germany 
Microtubes 1.5 ml  Thermo Scientific, USA 
Microtubes 0.2 ml  Thermo Scientific, USA 
Mr. Frosty™ Freezing Container Thermo Scientific, USA 
Pipettes (5-50 ml), sterile  Sarstedt, Germany 
Polystyrene round-bottom tube (5 ml) Becton Dickinson Falcon, Germany 
Syringes Omnifix 3 ml  B. Braun, Melsungen, Germany 
Tissue culture flasks T25  TPP, Switzerland 
Tissue culture flasks T75  TPP, Switzerland 
Tissue culture test plates 12 wells TPP, Switzerland 
 
Chemicals, drugs, solutions and media  
Agarose standard  Roth, Germany 
2-Mercaptoethanol  Sigma Aldrich, USA   
Biocoll Separating Solution Biochrom, Germany 
Citalopram hydrobromide Sigma Aldrich, USA  
Cyclosporine A  Sigma Aldrich, USA 
DMSO Sigma-Aldrich, USA 
DNA loading dye (6 x) Thermo Scientific, Germany 
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Dulbecco’s PBS (1x) PAA, Germany 
Ethanol 96% Merck, Germany   
Ethidium bromide Sigma Aldrich, USA 
FACS Flow BD Bioscience, Germany 
FACS Clean BD Bioscience, Germany 
FACS Rinse BD Bioscience, Germany 
Fetal Bovine Serum  Biochrom, Germany 
Fluoxetine hydrochloride Sigma Aldrich, USA   
Gene Ruler 50 bp DNA Ladder Thermo Scientific, USA 
Imipramine hydrochloride Sigma Aldrich, USA  
Interferon beta 1a (Rebif®) Merck, Germany 
L-glutamine  Biowest, France   
Penicillin/Streptomycin  Biowest, France   
RPMI 1640 Biowest, France 
Sodium chloride Carl Roth GmbH, Germany 
 
Kits 
AllPrep RNA/DNA Mini Kit  Qiagen, Germany 
Click-iT® EdU Alexa Fluor® 647 Flow Cytometry Assay Kit Life technologies, USA 
MycoAlertTM Plus Mycoplasma Detection Kit  Lonza, USA  
QiaShredder  Qiagen, Germany  
QuantiTect SYBR® Green PCR Kit  Qiagen, Germany 
SurePrint G3 Human Gene Expression 8x60K Microarray Kit Agilent Technologies, USA 
Transcriptor First Strand cDNA Synthesis Kit Roche, Germany 
TritestTM Kit Becton Dickinson, Germany 
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cell sex age
line week 0 week 5 week 8 0 1 2 3 4 5 6 7 8 0 1 2 3 4 5 6 7 8 0 1 2 3 4 5 6 7 8 0 1 2 3 4 5 6 7 8 0 1 2 3 4 5 6 7 8 0 1 2 3 4 5 6 7 8 0 1 2 3 4 5 6 7 8 0 1 2 3 4 5 6 7 8 0 1 2 3 4 5 6 7 8 0 1 2 3 4 5 6 7 8 0 1 2 3 4 5 6 7 8
96 f 45 23 17 15                                                                 
718 m 40 32 12 1                                                                               
719 f 51 23 17 12                                                                    
720 f 50 15 0 0                                                       
721 m 52 32 20 19                                                                         
722 f 68 31 13 4                                                     
725 m 66 21 0 0                                                   
728 m 38 40 9 15                                                                    
729 f 52 17 16 6                                                                          
730 f 53 39 0 0                                              
731 f 73 33 19 19                                                         
732 m 30 24 7 0                                                                             
734 m 43 27 5 0                                                     
735 m 23 30 4 2                                                                  
738 m 58 35 6 4                                                               
739 m 54 29 14 13                                                                    
740 m 41 36 28 22                                                                 
741 m 56 26 0 0                                                     
744 m 56 21 17 13                                                                     
751 f 45 31 16 10                                                                        
756 m 57 31 4 0                                                 
757 f 51 27 14 10                                                                                
792 m 62 30 23 21                                                                      
805 f 75 29 21 26                                                            
807 f 54 24 18 21                                                                   
881 m 48 29 23 19                                                                                 
882 m 49 31 17 16                                         
886 m 51 27 21 19                                                                                 
1069 m 32 28 6 5                                                              
1072 f 52 19 15 11                                                                 
1075 f 50 22 12 14                                                               
2123 f 53 14 16 15                                                                                  
2161 m 44 12 17 22                                                                
2411 f 70 23 21 23                                                                       
2741 f 63 25 17 17                                                                                           
2757 m 52 35 19 17                                                                    
1WXV f 60 31 18 8                                                                                
20XP f 22 31 28 27                                                                  
217x f 58 24 11 13                                                   
24CY f 55 5 12 11                                                           
24DC m 25 22 9 7                                                                                           
24DL f 41 36 32 24                                                                                
24E4 m 54 26 0 0                                                       
275J f 48 30 14 16                                                            
275U f 48 24 8 10                                                                                       
278D f 61 27 9 6                                                   
278H f 55 20 12 14                                              
278S m 40 34 11 2                                                                
278Y f 37 11 12 14                                                               
2EMM f 62 37 2 0                                              
2EN5 f 44 33 23 10                                                                  
2EOV f 42 28 26 19                                                                      
VO24 m 48 31 28 31                                                                
sleep medicationmood stabilizers benzodiazepinesSSRE Others neurolepticsHamilton TCA SSRI SNRI NASSA NARI
Abbreviations: f (female), m (male), TCA (tricyclic antidepressants), SSRI (selective serotonin reuptake inhibitors), SNRI (serotonin-norepinephrine reuptake inhibitors), 
NaSSA (noradrenergic and specific serotonergic antidepressant), NARI (noradrenalin-reuptake-inhibitor), SSRE (selective serotonin reuptake enhancer)  
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STAR*D cell lines 
 
 
 
 
cell line anxious sex age citalopram 
depression dose [mg] week 0 week 2 week 4 week 6 week 9 week 12 week 14
396613 Yes         f      47 10 21 13 13 16
482572 Yes m 43 20 24 23 22 10 18
14951 Yes m 53 20 19 15 19 10 14
15100 No          m        38 10 17 15 14 10 10
14754 No          f      49 20 23 11 13 13 5 8
15920 Yes         m        61 20 22 19 21 18 19 18
566271 No          f      38 20 16 13 15 11 13
18132 No          m        32 20 15 17 17 17
232816 Yes m 63 10 17 16 14 18 19 21
407004 Yes         m        56 20 14 13 15 15
279249 No          m        52 20 19 15 18 15 17
17326 Yes         m        43 20 21 11 11 8
14605 No m 52 20 19 20 20 16 20
402264 Yes         f      24 20 22 17 19
521742 Yes         f      42 20 18 18 6 16 10 9
368252 No          f      55 40 15 6 21
301611 No          f      52 20 14 18 17 12
592780 Yes         m        55 20 16 13 14 14 16
613529 Yes         f      52 20 19 19 19 19 19
635406 Yes         m        56 20 21 19 7 14
478406 No          f      55 10 18 12 15 17
437434 No          m        42 20 16 17 15 18
572045 Yes         m        57 20 20 13 15 8 13
578879 Yes         f      60 20 22 14 13 14 14
684462 Yes         f      43 20 24 20
367664 Yes         f      27 20 19 17 13 6 0 0
375024 Yes m 53 10 15 14 17 9 7 4
14132 No          m        28 20 16 3 6 2 1 2
755591 Yes         f      54 20 21 19 14 2 2 15 1
443508 Yes         m        42 20 23 22 12 6 5 2
311634 No m 70 20 15 8 5 2
15269 Yes         f      66 20 16 3 10 4 3 4 5
14267 Yes         f      53 20 16 13 9 1 2 0
17853 Yes m 32 20 20 9 6 9 7 2
362372 No          f      42 5 17 6 10 11 1
17827 Yes         m        55 20 13 8 4 6
234078 Yes         f      48 10 17 12 6 3 3
16718 Yes         f      38 20 20 12 9 6 4 2
14451 Yes         f      26 10 12 11 8 6 2 1
466830 No          f      68 10 16 9 7 5 2 1
330833 No          m        44 20 15 16 3 3 4 0
352423 No          f      48 20 17 8 3 3 1
409700 No          f      65 10 12 8 5 5 2 1
323701 No          m        28 20 16 8 9 7 4 4
510496 Yes         f      60 20 18 19 9 8 4
400643 No          f      35 20 15 12 10 4 3 4
411724 Yes m 69 10 19 13 6 7 4 5
17563 No          m        53 20 13 11 13 13 10 7
546797 Yes         f      49 20 18 14 9 11 8 3
550878 Yes         f      54 20 23 21 16 7 5 3
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